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V(D)J recombination is the process that generates the primary antigen receptor repertoire of the 
adaptive immune system. This process involves the ordered rearrangement of gene segments 
within antigen receptor loci and is initiated by the V(D)J recombinase, comprised of the 
recombination activating gene 1 and 2 proteins (RAG-1 and RAG-2). V(D)J recombination 
involves the programmed introduction of DNA double stranded breaks in the genome and is 
therefore tightly regulated to ensure genomic stability. Epigenetic regulation of V(D)J 
recombination by trimethylation at lysine 4 of histone 3(H3K4me3) is modulated through the 
plant homeodomain (PHD) of RAG-2. Binding of the RAG-2 PHD to H3K4me3 couples V(D)J 
recombination to active transcription and H3K4me3 allosterically activates RAG. In this 
dissertation, we demonstrate that the binding and allosteric activation of H3K4me3 are separable 
functions of the RAG-2 PHD.  
 
Temporal regulation of V(D)J recombination is an additional method of preserving genomic 
integrity. RAG-2 undergoes periodic destruction at the G1-to-S transition through 
phosphorylation at T490 and subsequent degradation by the ubiquitin-proteasome pathway. This 
limits RAG activity to the G1 cell cycle phase, during which nonhomologous end joining (NHEJ) 
is the predominant form of DNA double stranded break repair. In this dissertation, we employ a 
mouse model in which RAG-2 protein is constitutively expressed and DNA double stranded 
breaks accumulate throughout the cell cycle. To characterize genomic rearrangements that result 
from misregulated RAG activity, we developed a capture-sequencing approach. We demonstrate 
that this method is capable of identifying endogenous V(D)J rearrangements and novel 
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Chapter 1: Binding and allosteric transmission of histone 3 Lys-4 
trimethylation to the recombinase RAG-1 are separable functions of the 






V(D)J recombination is initiated by the recombination-activating gene (RAG) recombinase, 
consisting of RAG-1 and RAG-2 subunits. The susceptibility of gene segments to cleavage by 
RAG is associated with gene transcription and with epigenetic marks characteristic of active 
chromatin, including trimethylation of histone H3 at lysine 4 (H3K4me3). Binding of H3K4me3 
by a plant homeodomain (PHD) in RAG-2 induces conformational changes in RAG-1, 
allosterically stimulating substrate binding and catalysis. To better understand the path of 
allostery from the RAG-2 PHD finger to RAG-1, here we employed phylogenetic substitution. 
We observed that a chimeric RAG-2 protein in which the mouse PHD finger is replaced by the 
corresponding domain from the shark Chiloscyllium punctatum binds H3K4me3, but fails to 
transmit an allosteric signal, indicating that binding of H3K4me3 by RAG-2 is insufficient to 
support recombination. By substituting residues in the C. punctatum PHD with the corresponding 
residues in the mouse and testing for rescue of allostery, we demonstrate that H3K4me3 binding 
and transmission of an allosteric signal to RAG-1 are separable functions of the RAG-2 PHD 






The human immune system 
The human body is continually challenged by viruses, bacteria, and other pathogens. To prevent 
and eliminate infections, the immune system has evolved to recognize, clear, and remember 
pathogens. The human immune system is comprised of two arms, a nonspecific but rapid 
response called the innate immune system and a highly specific but slower response called the 
adaptive immune system. Innate immunity consists of both physical barriers like skin and mucus, 
as well as cellular and protein systems such as white blood cells, the complement system, and 
nucleic acid sensors that recognize pathogen associated molecular patterns. The highly antigen 
specific response of the adaptive immune system is carried out by lymphocytes, specifically B 
cells and T cells. B cells are capable of producing antigen-specific antibodies and B cell 
receptors (BCRs), collectively termed immunoglobulins (Ig), whereas T cells produce antigen-
specific T cell receptors (TCRs) that recognize foreign peptides.  Ig and TCR contain variable 
domains that are responsible for binding antigen, and constant domains responsible for effector 
functions. The genes that encode Ig and TCR are assembled by the process of V(D)J 
recombination. Igs are comprised of light and heavy chain polypeptides encoded by the 
immunoglobulin heavy chain locus (IGH) and the immunoglobulin κ or λ light chain loci (IGK, 
IGL) respectively.  TCRs are encoded by the TRB, TRAD, and TRG loci. These loci specify 
polypeptides that assemble into αβ or γδ heterodimers.  
 
Overview of V(D)J recombination 
Antigen receptor genes are present in the germline as discrete segments, termed variable (V), 
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diversity (D), and joining (J), that are joined during lymphocyte development by V(D)J 
recombination (1). V(D)J recombination is initiated by a specialized transposase (2), composed 
of RAG-1 and RAG-2 subunits, which cleaves DNA at recombination signal sequences (RSSs) 
that flank the participating gene segments (3). There are two classes of RSSs, termed 12-RSS 
and 23-RSS, in which heptamer and nonamer elements are separated by spacers of 12 bp or 23 
bp. DNA cleavage requires the pairing of a 12-RSS with a 23-RSS (3).  Rearrangement is 
initiated by nicking of DNA by RAG at the junction of each gene segment with its flanking RSS, 
followed by transesterification to produce double-strand breaks. The resulting coding and signal 
ends are then joined by non-homologous end joining to produce coding joints and signal joints 
(1,4). The catalytic and DNA-binding functions reside largely within RAG-1, but RAG-2 is also 
essential for DNA cleavage, contributing to DNA-binding and stabilization of the active site (5).  
The carboxy-terminal quarter of RAG-2 is dispensable for DNA cleavage but carries out several 
regulatory functions, including binding of RAG-2 to H3K4me3, an epigenetic mark of active 
chromatin  (6-8).  V(D)J recombination is preceded by the appearance of non-coding transcripts 
at the unrearranged locus (9,10) and the deposition of H3K4me3 (6,7,11-15), which binds to a 
plant homeodomain (PHD) finger spanning residues 415 through 487 of mouse RAG-2 (8,16).  
Engagement of H3K4me3 promotes recombination in vivo (6,7) and stimulates coupled cleavage 
of RSS substrates in vitro (17-19), consistent with allosteric activation.  In agreement with this 
interpretation, binding of H3K4me3 by the RAG-2 PHD finger is associated with changes in the 
conformational distribution of RAG-1 (20). 
 
The V(D)J recombinase: RAG-1 and RAG-2 
Initial DNA transfer experiments suggested that the V(D)J recombinase was encoded by a single 
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gene expressed in lymphoid cells (21). Through a series cDNA transfection experiments, the 
gene encoding RAG-1 was identified and shown to be critical for V(D)J recombination (22). The 
RAG-1 protein contains 1040 amino acid residues in mouse and 1043 amino acid residues in 
human (22). Mouse and human RAG-1 coding regions share 86% identity and close to 95% 
similarity indicating a high degree of evolutionary conservation. Similar genes were identified 
soon thereafter in rabbit, dog, goat, and horse (22).  
 
Upon further inspection, the coding sequence of RAG-1 was found to be the product of a single 
exon that was much smaller than the active, 12 kb genomic clone that was initially described. 
This, together with evidence that the RAG-1 cDNA was no more efficient in activation of 
recombination than bulk genomic DNA, suggested that the active genomic clone contained a 
second, tightly linked gene that was required in addition to RAG-1 for V(D)J recombination. A 
cDNA clone derived from this second gene, encoding a protein termed RAG-2, was found to act 
synergistically with RAG-1 cDNA to activate V(D)J recombination (23). The genes encoding 
RAG-1 and 2 are convergently transcribed and only 8 kb apart on chromosome 11p of humans 
and chromosome 2p of mice (24). The method used to identify the V(D)J recombinase would not 
have been fruitful if the two genes were not located together in the genome. 
 
Both RAG-1 and RAG-2 are essential for V(D)J recombination. RAG-2 deficient mice exhibit 
severe combined immunodeficiency (SCID), characterized by complete loss of mature B or T 
lymphocytes and a lack of antigen receptor loci rearrangements (25). This deficiency could be 
rescued in cell lines by the introduction of wild-type RAG-2. Since the only abnormal phenotype 
observed in these mice was the SCID phenotype, this data suggested that RAG-2 function and 
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V(D)J recombination are not required for development of cells outside of the lymphoid lineage 
(25). RAG-1 deficient mice also exhibit SCID, have no mature B or T cells, and exhibit a lack of 
antigen receptor rearrangements (26). Together these RAG deficient mouse models demonstrate 
the importance of RAG-1 and RAG-2 in V(D)J recombination.  
 
Evolution of RAG-1 and RAG-2 
Mechanistically V(D)J recombination is very similar to transposition. RAG-1 and RAG-2 may 
have evolved from components of a transposable element about 450 million years ago (27). This 
notion is supported by the observation that in vitro RAG-1 and RAG-2 are capable of acting as a 
transposase, excising a piece of DNA containing RSS from a donor site and inserting the DNA 
into a target DNA molecule (28). This results in a short duplication of the target DNA just as 
transposition events are characterized by target site duplications. Although RAG-1 and RAG-2 
can act as a transposase in vitro, there has not been much evidence of this activity in vivo. This 
could be explained by the additional levels of regulation imposed on this system in vivo.  
 Several regulatory mechanisms may suppress transposition in vivo. One mode of 
regulation is GTP-mediated inhibition. RAG-mediated transposition is suppressed by the 
physiological concentration (0.5 mM) of guanine nucleotide (GTP), which blocks the capture of 
target DNA (29). RAG transposition in vitro is inhibited by GTP at concentrations of 1mM or 
higher, which blocks target capture in the signal-end complex(30). This mode of regulation is 
also found for other transposases such as Tn7, bacteriophage Mu, and Drosophila P element(30). 
While one study has  suggested that the non-core region of RAG-2 can suppress transposition 
(30), this has been contradicted by a subsequent study in which core and full-length RAG signal 
end complexes exhibited similar transposition frequencies (31). Magnesium at physiologic 
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concentrations of 20 - 25mM can suppress transposition by favoring the disintegration of 
branched transposition intermediates, essentially reversing the process of transposition(30). A 
recent structure of RAG in a DNA-strand transfer complex revealed the presence of sharp kinks 
and twists in the DNA which could attenuate transposition(32). 
 
The identification of putative ancestral RAG proteins further supports the transposon origins of 
RAG. Two ancestral RAG-1 proteins, Transib transposase and purple sea urchin RAG-1 like, 
when coexpressed with RAG-2 are capable of initiating V(D)J recombination in vitro(33). 
Additionally, ProtoRAG, a DNA transposon from lancelets, is capable of mediating transposon 
excision, host DNA recombination, and transposition utilizing mechanisms similar to those 
employed by vertebrate RAG(34). These findings are consistent with a transposon origin of RAG; 
however, it remains possible that RAG-1 and RAG-2 may have independent evolutionary origins. 
RAG-1 is capable of mediating low levels of recombination in the absence of RAG-2, which 
permits the possibility that the two proteins may have evolved separately(35).  
 
Domain Structure of RAG-1 and RAG-2 
Murine RAG-1 and RAG-2 contain 1008 and 527 amino acid residues, respectively, of which 
residues 384-1008 of RAG-1 and 1-352 of RAG-2 are termed the core regions (36). These are 
the minimal regions required to perform RSS-dependent DNA cleavage in vitro(37,38). The core 
of RAG-1 is comprised of the nonamer binding domain (NBD), dimerization and DNA binding 
domain (DDBD), pre-RNase H fold (PreR) domain, the catalytic RNase H fold (RNH), two zinc 
binding domains ZnC2 and ZnH2, and a C terminal domain (CTD)(5). The core of RAG-1 
contains key catalytic residues needed for catalysis, a triplet of acidic residues commonly called 
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the DDE motif, which coordinate the divalent metal ion needed for catalysis(39-41). RAG-1 
specifically recognizes and binds to the recombination signal sequences (RSSs) in DNA(42-44). 
This recognition is mediated primarily through the NBD and DDBD domains within core RAG-
1(5). While RAG-2 is required for high-affinity binding to RSSs, recent structural data indicate 
that RAG-1 is largely if not solely responsible for binding DNA(5,45). The core of RAG-2 is 
comprised of six Kelch like motifs(5). In addition to these core domains, both proteins have 
extensive domain structures not included within the core domains. 
 
Beyond the core, RAG-1 contains several domains important for protein localization and 
regulation of V(D)J recombination. The N terminal region can enhance V(D)J recombination 
(46). There are several domains responsible for nuclear localization of RAG-1. Some of these 
regions serve as binding sites for the SRP1/Rch1 family of proteins. Rch1 specifically interacts 
with RAG-1 and is 47% identical to yeast SRP1, which is associated with the nuclear 
envelope(47). Once in the nucleus,  RAG-1 has been found to periodically localize to the 
nucleolus mediated through RNA interactions with RAG-1 domains containing basic amino 
acids(48). This nucleolar sequestration may serve to suppress V(D)J recombination(49). RAG-1 
contains a RING finger domain that acts as a ubiquitin ligase and can mediate auto-
ubiquitylation at a conserved Lys residue, K233 (50); disruption of this RING finger domain is 
associated with immunodeficiency(50). Furthermore, auto-ubiquitination of RAG-1 at residue 
K233 is associated with increased DNA cleavage activity(51). Together, this evidence suggests 
that the non-core regions of RAG-1 are important for both proper RAG-1 function and regulation 
of V(D)J recombination.  
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The non-core domains of RAG-2 also play important roles in the mechanism and regulation of 
V(D)J recombination. Early mutational studies revealed that the non-core carboxy-terminal 
portion of RAG-2 is dispensable for recombination(37,38). Although dispensable for 
recombination, the C-terminus of RAG-2 is essential for efficient VH to DJH rearrangement at the 
immunoglobulin heavy chain(IgH) locus(52). Other domains not included in the core consist of a 
non-canonical plant homeodomain (PHD), an inhibitory domain(ID), a degradation domain, and 
a nuclear localization signal (NLS) (8,17,53,54).  
The PHD of RAG-2 binds to the epigenetic mark histone 3 trimethylated at lysine 4 
(H3K4me3)(7,17). This binding of the PHD to H3K4me3 is necessary for efficient antigen 
receptor rearrangement. Crystal structures of the RAG-2 PHD alone, and the RAG-2 PHD 
complexed with modified histone 3 peptides identified the PHD as capable of recognizing two 
distinct histone modifications, H3K4me2 and H3K4me3(8). The RAG-2 PHD is different from 
canonical PHDs because the RAG-2 PHD contains a Tyr instead of an arginine. Usually PHD 
binding to H3K4me3 is inhibited by the demethylation of arginine, but the RAG-2 PHD results 
in improved binding to H3K4me3 by the demethylation of arginine(8). Additionally, mutations 
in this region are linked to the pathogenesis of severe combined immunodeficiency (SCID) and 
Omenn syndrome(55,56).  
The presence of an inhibitory domain was suggested by the paradoxical evidence that mutation 
of W453 in the PHD is more detrimental to recombination than the removal of the whole non-
core domain(17). The inhibitory domain spans from residues 352-405 and is highly acidic 
(17,54). Disruption of the inhibitory domain by neutralization of the acidic residues to alanines, 
stimulates V(D)J recombination on both extrachromosomal substrates and at endogenous antigen 
receptor loci(54). Additionally, this disruption permits association of RAG with the IgH locus in 
the absence of H3K4me3 binding.  
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Other important regulatory domains in the non-core of RAG-2 are the degradation domain and 
the NLS. V(D)J recombination is temporally controlled through the periodic degradation of 
RAG-2. RAG-2 is phosphorylated at T490 by CyclinA/CDK2 at the G1-to-S cell cycle transition 
leading to subsequent ubiquitylation by the Skp2-SCF E3 ubiquitin ligase and proteasomal 
degradation(57-60). The periodic destruction of RAG-2 links V(D)J recombination to the cell 
cycle by restricting RAG activity to G0/G1(61). This coupling of V(D)J recombination to the 
cell cycle suppresses genomic instability and lymphoid tumorigenesis(62). In addition to the 
modes of regulation imparted by these non-core domains, the NLS is required for efficient 
nuclear localization of RAG-2 in cycling cells. RAG-2 is imported into the nucleus via binding 
of Importin 5 to residues 499-508 of RAG-2(63).  
While the core domains of RAG-1 and RAG-2 are the minimal regions needed for DNA 
cleavage in vitro, these truncated proteins still exhibit reduced recombination levels in 
comparison to their full length counterparts(64). Of particular note, truncated RAG proteins 
generate 10 fold higher levels of signal ends, suggesting that the dispensable regions of RAG are 
involved in the proper processing of recombination intermediates(64). Mice containing core 
RAG-2 exhibit significant in vivo function, but have a reduced number of total B and T cells, 
indicating impaired lymphocyte development at the lymphocyte progenitor stages(65,66). These 
mice also exhibit defective ordered rearrangements, in which the numbers of V-to-D 
rearrangements within tri-partite antigen receptor loci are elevated and there is a defect in proper 
VH-to-DJH recombination at the IgH locus (67,68). Mice expressing core RAG-1 and core RAG-2 
exhibit an increase in aberrant V(D)J recombination and an increase in joins between signal and 
coding ends, termed hybrid V(D)J joins, suggesting that the non-core domains play a role in 
generating proper rearrangements (69,70). 
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Mechanism of V(D)J recombination 
V(D)J recombination is the process by which functional antigen receptor genes are assembled 
from V, D and J gene segments. Each V, D and J gene segment family has multiple members, 
which can be combined with other gene segments in a different family to produce a 3.5 x106  
potential V(D)J and VJ combinations(71). This combinatorial diversity, in combination with 
junctional diversity introduced by nucleotide loss and N and P nucleotide insertions, allows the 
immune system to recognize and respond to nearly any epitope with 1011 possible receptors(71). 
In brief, V(D)J recombination involves both the recognition of RSSs flanking antigen receptor 
gene segments by RAG-1 and recognition of H3K4me3 by RAG-2. After recognition of an RSS, 
RAG synapses two RSSs and induces a nick at the 5’ end of the first heptamer. This is followed 
by a transesterification reaction which produces a hairpin at each coding end and a blunt, 5' 
phosphorylated break at each signal end. The coding joint hairpins are subsequently opened by 
Artemis and then joined by the classical non-homologous end joining machinery.  
 
The first step in DNA cleavage requires RAG-1 binding of DNA. RAG-1 binds RSS DNA with 
3-5 fold preference over a random sequence DNA, whereas RAG-2 doesn’t exhibit direct 
binding of DNA(72). However, both RAG-1 and RAG-2 are needed for effective discrimination 
between an RSS and nonspecific sequences, as the RAG-1/RAG-2/RSS complex is more stable 
and specific than the RAG-1/RSS complex alone.  
 
Cell free reactions followed by in vitro studies using purified proteins demonstrated that RAG-1 
and RAG-2 are sufficient to perform DNA cleavage. In vitro coupled cleavage assays using 
radiolabeled DNA substrates and purified proteins revealed that upon synapsis of two RSSs, 
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nicking occurs prior to hairpin formation and that both RAG-1 and RAG-2 are required for nick 
and hairpin formation(73,74). RAG-1 introduces this nick at the junction of an RSS heptamer 
and the coding sequence; subsequent transesterification results in the formation of hairpins on 
the coding ends and blunt breaks on the signal ends(73,75). The coupled cleavage reaction 
requires two RSSs with spacers of 12 and 23 bp, a restriction known as the 12/23 rule(76).  
 
This 12/23 rule is established prior to DNA cleavage(77). The spacer ensures that there is an 
appropriate distance between the heptamer and nonamer of the RSS, and also regulates activity 
by providing additional RAG:RSS interaction surfaces(78). The 12/23 rule not only imparts 
specificity but also is involved in recruitment of RAG-1. RAG-1 is recruited most efficiently to 
substrates with a 12/23 RSS pair(79). Heptamer, spacer, and nonamer elements are all required 
for coupled cleavage in vivo(80). Within the RSS, the nonamer is important for initial binding 
and some coordination of nick and hairpin formation(81). Mutation of this nonamer leads to 
reduced stability of RAG with substrate DNA(82). In contrast, the heptamer is important for 
hairpin formation and mutation of the heptamer does not affect the stability of the RAG-RSS 
complex(82). The heptamer, specifically the three nucleotides (CAC) adjacent to the coding 
sequence, is essential for V(D)J recombination(83).  
 
Additional junctional diversity is introduced into the coding joint by the location of hairpin 
opening, potential insertions/deletions by the NHEJ machinery, and the addition of nontemplated 
nucleotides (N regions) by terminal deoxynucleotidyl transferase (TdT). The hairpinned coding 
ends are opened by Artemis (84,85). Coding joints are then formed by the classical NHEJ 
machinery. XRCC4 and Ku are required for both DSB repair and V(D)J recombination. Ku is a 
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heterodimer of 70 and 86kDA subunits, which binds to DNA broken ends (85). Ku is required 
for efficient V(D)J recombination as Ku86 deficient mice are defective in forming coding or 
signal joints and exhibit coding joints without N regions (86). After Ku binding, DNA-PKcs and 
TdT are recruited to the DNA ends and DNA-PKcs can phosphorylate its substrates(87-89). 
Additional diversity is introduced at the coding junction by terminal deoxynucleotidyltransferase 
(TdT) which inserts nontemplated (N) nucleotides(90-92) and palindromic (P) nucleotides 
created through the asymmetric opening of the hairpin(93). The final step of classical NHEJ 
involves the ligation of DNA by DNA ligase IV(87) to form a coding joint and a signal joint. 
 
3-Dimensional structure of RAG-1 and RAG-2 
The first crystal structure of RAG-1 and RAG-2 revealed that the V(D)J recombinase adopts a 
‘Y-shaped’ conformation consisting of a heterotetrameric complex with two subunits of RAG-1 
and two subunits of RAG-2, however DNA was not visible in this structure(5). Initial evidence 
for this model came from coimmunoprecipitation experiments demonstrating that RAG-1 and 
RAG-2 associate with each other within a complex(94). RAG-1 residues 504-1008 were 
sufficient to co-immunoprecipitate with RAG-2(95). Initial insights into the stoichiometry of the 
complex were incorrect, but further experiments demonstrated that core RAG-1 exists as a dimer 
when free in solution and this dimer was the minimal species bound to RSS(96). In addition to 
RAG-1 and RAG-2, the high mobility group protein HMG2 can be stably incorporated into the 
RAG-1/RSS complex. In the absence of RAG-2, HMG2 can increase the affinity of RAG-1 for 
RSS (96,97). The notion that HMG proteins can stabilize the RAG complex is supported by the 
evidence that HMG1 has greater affinity for RAG-1-DNA complexes than for RAG-1 or DNA 
alone(98).  
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Prior to the 2015 crystal structure, a number of structural insights came from smaller, domain-
specific studies. One such study demonstrated that the nonamer binding domain of RAG-1 forms 
a dimer that can bind and synapse two nonamer sequences(99). Fluorescence resonance emission 
transfer (FRET) experiments demonstrated that the 23-RSS is bent to facilitate the recognition of 
the heptamer and nonamer by RAG(100). RAG-1 alone can bind the nonamer, but RAG-2 is 
required for heptamer binding because it stabilizes RAG-1-heptamer interactions(101,102). 
Crystal and cryo-EM structures of RAG-1 and RAG-2 with DNA in the pre-reaction and hairpin 
forming complexes revealed that coding-flank DNAs extensively move and deform for nicking 
and hairpin formation(103). Recent cryo-EM structural studies in zebrafish RAG have detected 
DNA melting at the heptamer (103), in agreement with the results of earlier DNA modification 
interference experiments (101).  Heptamer melting is seen to place the scissile phosphate in the 
RAG-1 active site(104).  
Subsequent crystallographic analysis of core RAG-1 and core-RAG-2 in a signal-end complex 
confirmed many of the conclusions drawn from early structural insights. In particular the new 
data indicated that in a signal-end complex, RAG forms a ‘Y’ shaped structure in which the 
RAG-1 dimer forming the majority of the ‘Y’ with RAG-2 is located at the tip of each arm of the 
‘Y’ (5). RAG-1 contains an RNase H fold, in common with other DDE transposases. This 
structure revealed that RAG-2 contacts RAG-1 near the active site (5) but did not provide 
information regarding the non-core regions, which were absent. 
Several structures of the RAG-2 PHD, alone or in complex with histone 3 peptides, have been 
determined(7,8). Unlike other PHDs that bind histone H3K4me3, the RAG-2 PHD in complex 
with an H3K4me3 peptide lacks the canonical aromatic cage at the H3K4me3 binding site, 
which instead consists of an aromatic channel comprised of the highly conserved residues Y415, 
M443, and W453(7).  Additionally, structural analysis showed that five amino acid residues that 
are mutated in primary immunodeficiencies participate in histone H3 recognition(8). These 
structural studies suggested a connection between histone methylation and V(D)J recombination.   
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The most recent structural information comes from a cryo-EM structure of mouse RAG-1 
(residues 265-1040) and RAG-2 (residues 1-520) in complex with various DNA substrates(105). 
Unlike most DDE transposases, RAG first cleaves the upper strand at the 5’ boundary of the RSS 
with the coding sequence. In the pre-recombination complex (PRC) the RAG active site remains 
partially constructed and inactive, with only two of the acidic residues in close proximity(105). 
The active site then adopts two different configurations to performing nicking and hairpinning 
reactions in the nick forming complex (NFC) and hairpin forming complex (HFC) respectively. 
The PRC and NFC are similar from RAG-2 at the tip of the ‘Y’ structure through the NBD of 
RAG-1 in the ‘Y’ stem. However the NFC has ZnH2 domains that open outward upon binding to 
DNA in the PRC and then move inward when creating the NFC(105). This movement is also 
reflected in changes in contacts to the heptamer from PRC to NFC. In the NFC, a DNA zipper is 
formed which enables DNA unwinding and places the scissile phosphate in the active site(105). 
After hydrolysis, the 3’OH remains in the active site and serves as the nucleophile for producing 
a hairpin. 
After DNA cleavage, a stable post-cleavage complex is formed between synapsed recombination 
signal sequences, RAG-1, RAG-2,  HMG-1/HMG-2, and components of DNA-dependent protein 
kinase(106). A mutant form of RAG-1(S723C) is proficient for DNA cleavage but has defects in 
post-cleavage complex formation and end joining in vitro. A mouse model expressing the RAG-
1(S723C) mutation is a hypomorph which exhibits aberrant DNA double-stranded breaks, 
impaired lymphocyte development and decreased V(D)J joining(107). Early structural analyses 
of the post-cleavage complex indicated that the signal-end complex contains two protomers of 
RAG-1 and two protomers of RAG-2, a structure that was later confirmed(5,18). This complex 
has two fold symmetry and the N termini of RAG-1 and RAG-2 are positioned at opposing ends 
of the complex(18). 
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Regulation of V(D)J recombination 
The DNA breaks introduced by RAG are potentially deleterious, and V(D)J recombination is 
tightly regulated to mitigate genomic instability. Regulation of this process occurs in lineage- 
specific and developmental stage-specific fashion. One layer of this regulation involves the 
controlled expression of RAG-1 and RAG-2. 
 
V(D)J recombination is restricted to the B and T lymphoid lineages and this is enforced in part 
by restricted patterns of RAG-1 and RAG-2 expression (108). RAG-1 and RAG-2 are 
exclusively expressed in the lymphoid lineage and in a developmentally regulated fashion. For 
example within the T lineage, RAG-1 and RAG-2 are both expressed in immature CD4+CD8+ 
(double positive) T cells, but not in more mature CD4+CD8- or CD4-CD8+(single positive) 
subpopulations (109). The promoter of RAG-2 is lymphoid specific, but is regulated differently 
in B cells and T cells (110). In B cells, the B-cell-specific transcription factor BSAP/Pax-5 can 
bind to the promoter, while in T cells c-Myb regulates the RAG-2 promoter (111). In B cells, a 
conserved transcriptional enhancer termed Erag is essential for expression off of RAG-1 and 
RAG-2 promoters(68).  C-Myb negatively regulates Foxo1 expression, an activator of RAG(112), 
and also occupies the Erag enhancer(112).. 
 
Within a lineage, RAG is also developmentally controlled. At the immunoglobulin locus, heavy 
chain rearrangement precedes light chain rearrangement, and within the heavy chain locus DH-to-
JH rearrangement occurs before VH-to-DJH rearrangement (113).  RAG transcript levels are high 
in pro-B and pre-B-I cells, in which in DH-to-JH and VH-to-DJH rearrangement occurs, lower in 
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large pre-B-II cells and high again in small preB-II cells, which undergo VL-to-JL 
rearrangement(114).  
 
Another mode of developmental regulation is imposed by chromatin remodeling. Alterations to 
nucleosome structure by chromatin remodelers, such as SWI/SNF that increase histone 
acetylation, can increase the accessibility of nucleosomal DNA to cleavage by RAG (115). 
Regulated accessibility of individual antigen receptor loci by histone marks helps to control the 
process of V(D)J recombination. Epigenetic alterations of chromatin at antigen receptor loci are 
regulated in a locus, lineage, and stage specific manner during B cell development(116). 
 
Beyond lineage and developmental regulation, V(D)J recombination is restricted to antigen 
receptor loci at the level of RAG-1 and RAG-2 discrimination. In vivo, RAG-1 binds only at 
regions containing RSSs while RAG-2 binds to thousands of genomic sites containing histone 3 
trimethylated at lysine 4 (H3K4me3)(117). I will expand upon epigenetic regulation of V(D)J 
recombination in the next section. Moreover, recombination appears to be topologically 
restricted to chromatin loops, which limits potential recombination events to those containing 
gene segments within special proximity to each other(118). This mode of restriction is discussed 
more fully in Chapter 2 of this dissertation. 
 
Transcription and epigenetic control of the RAG recombinase 
Transcription and V(D)J recombination are tightly linked(10).  Transcription of unrearranged VH 
gene segments is positively correlated with the targeting of these segments for V(D)J 
recombination(10).  This has suggested a model, termed the accessibility model, in which 
transcription establishes an open chromatin environment that provides accessibility to the V(D)J 
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recombinase. This model suggests that the lineage- and developmental stage specificity of V(D)J 
recombination are established by distinct patterns of transcription.  A causal relationship between 
transcription and recombination was suggested by the demonstration that transcription of 
neighboring genes enhances substrate recombination efficiency in a pre-B cell model with stably 
integrated recombination substrates(119). In agreement with the accessibility model, rearranged 
antigen receptor loci exhibit greater sensitivity to DNase1 digestion compared to unrearranged 
loci(120).  
 
Transcriptional control elements such as enhancers and promoters were identified within antigen 
receptor loci and upon recruitment of transcription factors, these elements could activate 
transcription and recombination(121). Further insights into these accessibility control elements 
came from studies examining the intronic IgH enhancer (Emu). Mutational analysis of 
transcriptional control elements showed that Emu is necessary for V(D)J recombination in 
developing B cells and IgH locus transcription in mature B cells(122-124). Enhancer deletion 
experiments at other antigen receptor loci yielded similar results, pointing to the importance of 
enhancers in regulating recombination(122,123,125-131). On a more local scale, transcriptional 
promoters can influence recombination. Deletion studies in the TRA and TRB loci demonstrated 
that removal of promoters can decrease recombination at proximal gene segments(126,132-134). 
Testing of the accessibility hypothesis led to the conclusions that enhancers control RAG-1 
binding globally, that promoters and transcription can direct RAG-1 binding locally, and that 
RAG-1 can be targeted to DNA in the absence of RAG-2 (135). 
 
The lineage-specificity and temporal ordering of antigen receptor loci rearrangement is reflected 
by the relative chromatin accessibility of the RSS(136,137). Chromatin states can inhibit 
recombination in vivo (138-141). Studies using chromatinized or naked DNA substrates 
demonstrated that ATP-dependent remodeling of chromatin can result in increased DNA 
cleavage by RAG(142). Accessibility of antigen receptor loci is also dependent on nucleosome 
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distribution. At the immunoglobulin heavy chain (IgH)  locus in pro-B cells, a nucleosome is 
positioned over each IgH variable coding gene segment which places the RSS in a position 
accessible to RAG(143). In contrast, in mouse embryonic fibroblasts, the IgH coding gene 
segments are depleted of nucleosomes, which then result in nucleosomes covering the RSS 
making the DNA inaccessible to RAG. In a cell-free system, recruitment of SWI/SNF 
chromatin-remodelers to an RSS increases coupled cleavage by RAG demonstrating a role for 
chromatin remodeling in V(D)J recombination(144). Additionally, depletion of SWI/SNF in pro-
B cells prevents antisense transcription at the IgH locus(145). Thus, changes in nucleosome 
positioning, in addition to chromatin modifications, may play a role in controlling V(D)J 
recombination during development.  
 
Within the IGH locus epigenetic marks help to constrain VH recombination to already 
recombined DJH junctions(137). These DJH junctions are marked with active histone marks, bind 
to RAG, and become nuclease sensitive(15). Analyses in RAG-deficient pro-B cells 
demonstrated that only the 5’ and 3’ most DH gene segments, and the JH segments have hallmarks 
of active chromatin. Additionally, the JH segments have the highest density of RAG proteins in 
the germline. H3 and H4 acetylation and H3K4dimethylation (H3K4me2) are restricted to the 5’ 
and 3’ most DH segments called DFL16.1 and DQ52, while DH gene segments in between are 
marked by the heterochromatic modification H3K9me2. This epigenetic pattern is reflected in 
recombination, where the DFL16.1 and DQ52 gene segment recombine more frequently than 
other D segments(11,146). Upon rearrangement, RAG becomes redistributed toward the DJH 
junctions(15). Chromatin immunoprecipitation analyses in Emu deficient cell lines demonstrated 
that Emu is necessary for the deposition of these active histone marks at the IgH locus(15). Both 
the germline and DJH rearranged loci lacked the active histone marks H3K4me3 and H3K9ac(15). 
These data further support the accessibility model and provide insight into the ordered 
rearrangement at the IgH locus. 
 
	 20 
The finding that RAG-2 binds to H3K4me3, and that this binding is essential for efficient 
rearrangement, provided a direct mechanistic link between transcription and V(D)J 
recombination. RAG-2 contains a PHD finger that specifically recognizes H3K4me3. Mutations 
that inhibit RAG-2 recognition of H3K4me3 decreased V(D)J recombination in vivo(6,7). A 
conserved tryptophan residue W453 is a key structural component of the H3K4me3 binding 
surface and is required for RAG-2 recognition of H3K4me3(6,7). Mutations of W453, 
specifically W453R, is associated with the primary immunodeficiencies termed Omenn 
syndrome (55). The pattern of RAG-2 binding to chromatin across the IgH locus is positively 
correlated with the distribution of H3K4me3(6).  
 
The requirement for H3K4me3 recognition can be bypassed by mutations within an inhibitory 
domain in RAG-2, whose disruption is associated with constitutive increases in RSS binding 
affinity, catalytic rate and recombination frequency, mimicking the stimulatory effects of 
H3K4me3 (17).  Association of RAG-1 and RAG-2 with the IgH locus in B cell progenitors is 
dependent on recognition of H3K4me3 by the PHD (117,147) and disruption of the inhibitory 
domain permits association of RAG with the IgH locus in the absence of H3K4me3 binding (54).  
Thus, the inhibitory domain blocks access of RAG to the IgH locus except when H3K4me3 is 
engaged by RAG-2(17,54).  RAG-1 binding is driven by both H3K4me3 via RAG-2 and also by 
H3K27Ac through the non-core portions of RAG-1(148). Not only does H3K4me3 bind to 
RAG-2, but it allosterically activates RAG and induces conformational changes in RAG-
1(6,17,20). Our understanding of the coupling between transcription and antigen receptor gene 
rearrangement has been advanced by the finding that epigenetic marks deposited during 




Taken together these observations suggest the following model for association of RAG with 
antigen receptor loci: (1) in the absence of H3K4me3, RAG has low affinity for the RSS; (2) 
when the RAG-2 PHD finger is engaged by H3K4me3, an allosteric signal is propagated to 
RAG-1, which acquires high affinity for the RSS; and (3) the binding of RAG to a nearby RSS 
stabilizes its association with the locus.  As a test of this model, we sought to identify mutations 
in the RAG-2 PHD finger that separate binding of H3K4me3 from allosteric activation of RAG-1.  
Here we employ a strategy of phylogenetic substitution to identify amino acid residues within the 
PHD finger, but distinct from the H3K4me3 binding site, that function in transmission of an 







It has remained unclear how information regarding the binding of H3K4me3 by RAG-2 is 
transmitted to RAG-1.  We hypothesized that such information is conveyed through a path 
involving amino acid residues within the PHD finger other than those that engage H3K4me3. To 
test this hypothesis, we sought to identify separation-of-function mutations in the RAG-2 PHD 
finger that impair V(D)J recombination but spare binding to H3K4me3.  
 
Phylogenetic substitution separates H3K4me3 binding from allosteric activation in vitro 
To decrease the complexity of the search we employed a phylogenetic approach, reasoning that 
RAG-2 PHD fingers from species distantly related to the mouse might retain the ability to bind 
H3K4me3 but be sufficiently different in sequence so that transmission of the allosteric signal to 
mouse RAG-1 might be impaired.  RAG-2 of the brownbanded bamboo shark, C. punctatum, is 
phylogenetically distant from that of the mouse (149).  In the interval spanning residues 414 
through 485 the RAG-2 PHD finger of M. musculus differs from that of C. punctatum at 25 
positions (Fig 1A).  When mapped onto a crystal structure of the mouse PHD finger (7), these 
differences largely reside opposite to the H3K4me3 binding pocket (Fig. 1B) and are potentially 
free to participate in an allosteric interface.   
 
The similarity of the M. musculus and C. punctatum PHD fingers in the region of the H3K4me3 
binding site suggested that the shark PHD finger would also be capable of binding H3K4me3.  
To test this, we constructed a RAG-2 chimera in which the mouse PHD finger was replaced by 
the PHD finger from C. punctatum.  Lysates of HEK293T cells expressing wild-type, murine 
RAG-2 or the murine RAG-2 bearing the C. punctatum PHD finger were incubated with a bead-
bound peptide corresponding to residues 1 - 21 of histone H3 and trimethylated at lysine 4 
(H3K4me3).  Both wild-type murine RAG-2 and the mouse-shark RAG-2 chimera bound to the 
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H3K4me3 peptide (Fig. 1C, right, lanes 1 and 3).  As expected, a W453A mutation in the 
H3K4me3 binding pocket of mouse RAG-2 abolished binding to H3K4me3 (Fig. 1C, right, lane 
2).  In addition, the KMT2D lysine methyltransferase, which carries multiple PHD fingers with 
specificity distinct from that of RAG-2, also failed to bind H3K4me3 (Fig. 1C, right, lane 4).    
 
We next asked whether the C. punctatum PHD finger could replace its murine counterpart in an 
assay for allosteric activation of coupled DNA cleavage by RAG.  The version of RAG-1 used in 
these assays, cR1ct, lacks the amino-terminal non-core region and is more soluble than the wild-
type protein but remains responsive to H3K4me3 (17,150).  Full-length, wild-type mouse RAG-2 
and chimeric RAG-2 bearing the C. punctatum PHD finger, both tagged at the amino terminus 
with MBP, were coexpressed individually with MBP-tagged cR1ct and RAG tetramers were 
purified by a protocol that removes endogenous H3K4me3 (20).  Equivalent amounts of each 
RAG tetrameric complex were assayed in vitro for coupled cleavage of a radiolabeled 12-RSS 
substrate in the presence of an unlabeled 23-RSS substrate and increasing amounts of a histone 
H3-derived peptide containing trimethylated lysine 4 (H3K4me3) or unmethylated lysine 4 
(H3K4me0).  As previously reported (17,19,150), formation of nicked product was stimulated in 
a dose-dependent manner by H3K4me3, but not by H3K4me0 (Fig 1D).  In contrast, the 
chimeric version of RAG-2 failed to be stimulated by H3K4me3 (Fig. 1D).  Similar results were 
obtained with independent protein preparations.  Taken together, these observations indicated 
that replacement of the mouse RAG-2 PHD finger with the PHD finger from C. punctatum 
produces a protein in which the H3K4me3-binding is retained while the ability to support 
allosteric activation of RAG-1 is lost.   
 
A RAG-2 PHD mutant that binds H3K4me3 without supporting V(D)J recombination in vivo 
We went on to test whether the binding of H3K4me3 could be separated from the ability of 
RAG-2 to support V(D)J recombination in vivo.  An initial assay for recombination of an 
extrachromosomal substrate (17,54,151) suggested that the mouse-shark chimeric RAG-2 
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(PHDPUNC) was impaired in its ability to support V(D)J recombination, as its activity was similar to 
that of RAG-2(W453A), which cannot bind H3K4me3, and of a chimeric RAG-2 mutant bearing 
the corresponding mutation, W455A in the C. punctatum PHD finger (Supplemental Fig. 1).   
 
We proceeded to a more extensive analysis, with the goal of identifying mutations that impair 
V(D)J recombination while disrupting neither protein expression nor the ability to bind 
H3K4me3.  Cassettes encoding wild-type RAG-2 and a series of variants, fused at the amino 
terminus to the FLAG epitope and at the carboxyl terminus to poly-histidine and myc tags (Fig. 
2A), were introduced into the retroviral vector pCLIP2a (152).  These included RAG-2(PHDPUNC), 
the chimera bearing the C. punctatum PHD finger in the context of mouse RAG-2.  As negative 
controls we tested RAG-2(W453A) and RAG-2(PHDPUNC, W455A) (Fig. 2A), in which an 
invariant tryptophan residue involved in H3K4me3 binding was mutated to alanine.  We have 
previously shown that disruption of the RAG-2 inhibitory domain permits V(D)J recombination 
to override the requirement for recognition of H3K4me3 (17,54).  It was therefore also of interest 
to assay RAG-2(D/E352-405A) and RAG-2(D/E352-405A, PHDPUNC) (Fig. 2A), in which the 
acidic residues within the inhibitory domain were mutated to alanine.  We constructed an 
additional set of mutants in which groups of amino acid residues in the C. punctatum PHD finger 
were mutated to the corresponding residues in the mouse.  Using the three-dimensional structure 
of the mouse PHD finger as a guide, we assigned these sequence differences to five groups, each 
of whose residues are closely clustered on the surface opposite the H3K4me3 binding site (Fig. 
2B and 2C), reasoning that one or more alterations on this surface might disrupt recombination 
but spare binding to H3K4me3.  These spatially clustered mutations, as depicted in Fig. 2B, were 
termed Group 1 (K418T, S420C, S421P, A422T, N424D), Group 2 (M425V, N426D, V427I, 
I429T, E431V, Y433F), Group3 (N460D, A462E, S464R, Q465T, Q468H, F469L), Group 4 
(Q471E, E472G, N473S, T474N) and Group 5 (F445Y, S448H, F477Y, Y482V), where the 
numbering follows that of the mouse sequence. 
 
	 25 
To assay recombination quantitatively we employed a fluorescent assay for recombination of an 
integrated substrate (153).  Retroviral constructs encoding the RAG-2 variants described in Fig. 
2A, as well as constructs encoding the clustered shark-to-mouse mutants, were used to infect the 
cell line R2K3, a RAG-2-deficient, Abelson murine leukemia virus (AbMuLV)-transformed B 
progenitor (153).  R2K3 contains an integrated substrate for V(D)J recombination whose 
inversional rearrangement results in the expression of GFP.  Following transduction of RAG-2 
recombination is induced by STI-571; rearrangement of the integrated substrate is detected by 
flow cytometry.  Cells transduced with wild-type RAG-2 exhibited increasing levels of GFP 
fluorescence, approaching a recombination frequency of 80 percent, over a period of at least 96 
hr following arrest with STI-571 (a representative analysis at 96 hr is shown in Fig. 3A; the 
results of three technical replicate assays at 48 hr and 96 hr are shown in Fig. 3B).  As expected, 
recombination was impaired by the W453A mutation, which disrupts binding of H3K4me3 (Fig. 
3A and 3B).  We also observed little recombination in cells transduced with the RAG-2(PHDPUNC) 
chimera or with RAG-2(PHDPUNC, W455A) (Fig. 3A and 3B).  Notably, the RAG-2(D/E352-405A, 
PHDPUNC) chimera, in which the inhibitory domain is neutralized, supported recombination to a 
level near to that of wild-type RAG-2 or RAG-2(D/E352-405A) (Fig. 3A and 3B, IDNEUTPHDPUNC), 
indicating that the chimeric protein can interact functionally with RAG-1 to support 
recombination when the requirement for H3K4me3 binding is bypassed.  Among the back-
mutated mutants, RAG-2(PHDPUNC, Group1) and RAG-2(PHDPUNC, Group4) showed sharply 
diminished recombination activity with respect to wild-type RAG-2, while RAG-2(PHDPUNC, 
Group 2), RAG-2(PHDPUNC, Group 3) and RAG-2(PHDPUNC, Group5) supported recombination at 
frequencies of about 38 to 75 percent that of wild-type (Fig. 3A and 3B).  
 
Because any impairment of recombination could result from decreased protein accumulation, we 
examined expression of each of the RAG-2 variants at 96 hr after arrest by STI-571, with the 
goal of identifying mutant proteins that are robustly expressed but fail to support efficient V(D)J 
recombination.  Accumulation of RAG-2(PHDPUNC) was reduced to less than one tenth that of 
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wild-type RAG-2 (Fig. 3C and Supplemental Fig. 2) and could not be rescued by overexpression 
of RAG-1 in a cotransfection assay (Supplemental Fig. 3).  Of the additional mutant proteins that 
exhibited impaired recombination in the R2K3 assay, only RAG-2(PHDPUNC, Group 1) was 
expressed at a level similar to those RAG-2 variants that retained recombination activity (Fig. 3C 
and Supplemental Fig. 2).  Thus, the Group 1 mutation permitted near normal accumulation of 
the RAG-2(PHDPUNC) chimeric protein but was associated with a large reduction in recombination 
activity.   
 
To confirm the effects of the RAG-2 mutations described above on V(D)J recombination, the 
R2K3 rearrangement assay was performed in biological triplicate, each biological assay 
consisting of three technical replicates (Fig. 3D).  Of note, cells transduced with RAG-2(PHDPUNC, 
Group 1) exhibited a large and statistically significant decrease in recombination frequency in 
comparison to cells transduced with wild-type RAG-2 or RAG-2(PHDPUNC, Group 2) (Fig. 3D, 
Group 1), while neutralization of the inhibitory domain robustly conferred recombination activity 
on the RAG-2(PHDPUNC) chimera (Fig. 3D, IDNEUT, PHDPUNC).   
 
A back mutation from shark to mouse sequence in the RAG-2 PHD that restores V(D)J 
recombination activity   
We considered that the impairment of recombination activity observed for the RAG-2(PHDPUNC, 
Group 1) mutant might result from disruption of intramolecular interactions that propagate the 
allosteric signal initiated by the binding of RAG-2 to H3K4me3.  To test this interpretation we 
asked: (1) whether the defect in recombination observed for RAG-2(PHDPUNC, Group 1) can be 
reversed by an additional back-mutation within the C. punctatum PHD finger; and (2) whether 
RAG-2(PHDPUNC, Group 1) retains the ability to bind H3K4me3.   
 
Because RAG-2(PHDPUNC, Group 2) robustly supported V(D)J recombination, the Group 2 back-
mutation was an attractive candidate for rescue of RAG-2(PHDPUNC, Group 1).   We observed that 
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a mouse-shark RAG-2 chimera bearing combined Group 1 and Group 2 mutations exhibited a 
robust increase in recombination frequency, relative to the Group 1 mutant (Fig. 4A and 4B, 
compare Group 1 to Groups 1+2).  In this assay the expression levels of RAG-2(PHDPUNC, 
Groups1+2), RAG-2(PHDPUNC, Group1) and wild-type RAG-2 differed by about two-fold or less 
(Fig. 4C).  Taken together, the results described above indicate that the Group 1 mutation 
enhances accumulation of the RAG-2(PHDPUNC) chimera without permitting recombination, and 
that additional back-mutation of the Group 2 cluster confers recombination activity on the Group 
1 mutant.  Consistent results were obtained with a similar recombination assay in which RAG-2 
variants were transduced using the pCST virus (Supplemental Fig. 4). 
 
To establish that RAG-2(PHDPUNC, Group 1) is indeed a separation-of-function mutant, we tested 
its ability to bind H3K4me3.  Wild-type mouse RAG-2, RAG-2(W453A), RAG-2(PHDPUNC), 
RAG-2(PHDPUNC, Group 1), RAG-2(PHDPUNC, Group 2) and RAG-2(PHDPUNC, Groups 1+2) were 
expressed as MBP fusions in HEK293 cells.  Lysates were incubated with beads coated with the 
H3K4me3 peptide or the corresponding unmethylated peptide (H3K4me0).  Bead-bound protein 
was detected by immunoblotting for MBP.  As expected, wild-type RAG-2 was capable of 
binding to H3K4me3 but not to H3K4me0, while RAG-2(W453A) bound neither peptide (Fig. 
4D).  Consistent with results presented above, RAG-2(PHDPUNC) was able to bind H3K4me3.  
Importantly, RAG-2(PHDPUNC, Group 1), RAG-2(PHDPUNC, Group 2) and RAG-2(PHDPUNC, Group 1) 
each exhibited binding to the H3K4me3 peptide, but not to H3K4me0 (Fig 4D).  Taken together 
the properties of the RAG-2(PHDPUNC, Group 1) mutant indicate that the ability of the RAG-2 





Binding of H3K4me3 to the RAG-2 PHD finger alters the conformation of RAG-1 and this is 
accompanied by enhancements of affinity for substrate and catalytic rate (6,7,17,19,20) These 
observations have suggested an allosteric model for activation of RAG.  According to such a 
model, binding of H3K4me3 by the RAG-2 PHD finger would be necessary but insufficient for 
activation of RAG-1.  The observations described here provide additional support for an 
allosteric model by demonstrating that activation of RAG-1 requires one or more functions of the 
RAG-2 PHD finger in addition to engagement of H3K4me3.   
 
An initial indication that H3K4me3 binding is insufficient for activation of RAG was provided 
by the RAG-2(PHDPUNC), which retains the ability to bind H3K4me3 but was unresponsive to 
allosteric activation in vitro by an H3K4me3 peptide under conditions in which equivalent 
amounts of wild-type RAG and chimeric mutant were compared.  Although this observation is 
consistent with allostery, we considered a more trivial explanation for loss of activity, namely, 
that RAG-2(PHDPUNC) may have undergone a structural alteration that renders it unable to support 
DNA cleavage, for example, by disrupting association with RAG-1.  This is rendered unlikely by 
the fact that disruption of the inhibitory domain restores the ability of the RAG-2(PHDPUNC) 
chimera to support recombination.  We therefore favor the interpretation that the PHD finger of 
C. punctatum is unable to transmit an activating allosteric signal to mouse RAG-1 upon binding 
of H3K4me3. 
 
Although RAG-2(PHDPUNC) satisfied biochemical criteria for a separation-of-function mutant, its 
poor expression in vivo precluded our ability to assess its function in V(D)J recombination.  By 
systematic reversion of RAG-2(PHDPUNC) residues specific to C. punctatum to those of the mouse, 
we identified three clustered mutations, RAG-2(PHDPUNC, Group2), RAG-2(PHDPUNC, Group3) and 
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RAG-2(PHDPUNC, Group5), which were able to confer recombination activity.  Because each of 
these mutations also restored protein accumulation to an amount similar to that of wild-type 
RAG-2, their stimulatory effect on recombination may have been a consequence of increased 
expression. Alternatively, or in addition, these mutations may have effected an increase in the 
affinity of the PHD finger for H3K4me3 or enhanced the efficiency with which information 
regarding the engagement of H3K4me3 is transmitted to RAG-1.  In this regard it should be 
noted that the clustered Group 3 and Group 5 mutations reside near the H3K4me3 binding site.  
 
The RAG-2(PHDPUNC, Group1) mutant, like RAG-2(PHDPUNC, Group2), RAG-2(PHDPUNC, Group3) 
and RAG-2(PHDPUNC, Group5), was expressed robustly in vivo.  Unlike RAG-2(PHDPUNC, Group2), 
RAG-2(PHDPUNC, Group3) and RAG-2(PHDPUNC, Group5), RAG-2(PHDPUNC, Group1) exhibited a 
large and significant reduction in the ability to support V(D)J recombination, even though it 
retained the ability to bind H3K4me3. Thus, with respect to recombination RAG-2(PHDPUNC, 
Group1) represents a separation-of-function mutant.  We considered the possibility that RAG-
2(PHDPUNC, Group1) may have suffered an overall, debilitating structural lesion but consider this 
unlikely because RAG-2(PHDPUNC, Groups1+2), in which the Group 1 and Group 2 mutations are 
combined, exhibited full function.  Lastly, we considered that RAG-2(PHDPUNC, Group1) may 
have exhibited a loss of function because of an inability to interact with an essential factor other 
than RAG-1.  This is unlikely because allosteric activation of coupled RSS cleavage does not 
require components other than RAG-1, RAG-2 and H3K4me3 peptide.   
 
Available RAG structures do not include the PHD finger and therefore do not provide 
information regarding its interactions (5,154,155).  A recent study (156) provides evidence for an 
interaction between RAG-1 and the dispensable region of RAG-2 but the structural basis for this 
interaction remains unexplored.   The Group 2 mutation, which converted six residues in the C. 
punctatum PHD finger - M425, N426, V427, I429, E431 and Y433 - to the corresponding 
residues of the mouse was able to restore function to the RAG-2(PHDPUNC, Group1) mutant in an 
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assay for V(D)J recombination.  The ability of the Group 2 mutation to rescue RAG-2(PHDPUNC, 
Group1) is not likely to be the result of effects on protein accumulation or H3K4me3 binding, 
although the latter possibility is not excluded by the available data.  This result strongly suggests 
that in the mouse RAG-2 PHD finger one or more of the residues V425, D426, I427, T429, V431 
and F433 participate in the relief of autoinhibition exerted by the RAG-2 inhibitory domain, 
either through transmission of the H3K4me3 allosteric signal or in some other, as yet undefined 
way.  Because the mutational strategy employed here was restricted to amino acid sequence 
differences between M. musculus and C. punctatum, it remains likely that other residues 
contribute to the activation of RAG-1 in response to H3K4me3.    
 
Although the PHD finger of RAG-2 from C. punctatum binds H3K4me3 it has not, to our 
knowledge, been determined whether the C. punctatum RAG ortholog is subject to allosteric 
activation by H3K4me3.  Alignment of RAG-2 from M. musculus and C. punctatum does, 
however, reveal 43 percent sequence identity within the interval from residues 352 through 405 
of the mouse, corresponding to the inhibitory domain (54) Moreover, the corresponding C. 
punctatum sequence, like that of the mouse, is highly acidic, suggesting the presence of an 
autoinhibitory function within RAG-2 of C. punctatum that may be relieved by H3K4me3.  
 
The PHD finger of human RAG-2 is a frequent target of mutations associated with primary 
immunodeficiency diseases (157).  Disease-associated missense mutations have been identified 
at thirteen sites within the PHD; mutations at eight of these residues have been found in patients 
with Omenn syndrome, a primary immunodeficiency disorder characterized by pathogenic 
oligoclonal T cell expansion and profound B lymphopenia (55,157-159) The remaining 
mutations are associated with severe combined immunodeficiency (SCID), atypical severe 
combined immunodeficiency or combined immunodeficiency with granulomas and/or 
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autoimmunity (157,159). Several of these mutations, including those at invariant residues C446 
and C478, which participate in the formation of a zinc finger, are expected to disrupt the three-
dimensional structure of the domain (7,55).  Other mutations, including those at residues M443 
and W453, abrogate binding of H3K4me3 (6,7). Thus, several RAG-2 mutations associated with 
primary immunodeficiency can be inferred to disrupt allosteric activation of RAG-1 by 
H3K4me3.  Of the known disease-associated mutations in the RAG-2 PHD only one, N474S, is 
contained within one of the clustered mutations tested in this communication; all of the others 
affect residues that are conserved between M. musculus and C. punctatum.  Notably, the N474S 
mutation does not impair the ability of RAG-2 to support V(D)J recombination (55,159) 
suggesting that in this case one or more other mutations are responsible for the disease 
phenotype.  Pathogenic mutations within the RAG-2 PHD at sites other than N474 are associated 
with impaired V(D)J recombination activity (55,159), and it remains possible that one or more of 
these mutations interferes with allosteric transmission of the H3K4me3 signal to RAG-1. 
 
Summary and Future Directions 
V(D)J recombination is associated with gene transcription and epigenetic marks of active 
chromatin such as H3K4me3. Binding of H3K4me3 by the RAG-2 PHD results in 
conformational changes in RAG-1 and allosteric activation of RAG. In this chapter, we have 
demonstrated that H3K4me3 binding and transmission of the allosteric signal to RAG-1 are 
separable functions of the RAG-2 PHD finger. Additionally, we have begun to identify the path 
of allostery from the RAG-2 PHD finger to RAG-1.  
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To build upon this work, it would be interesting to further utilize the RAG-2(PHDPUNC, group1) 
separation of function mutant to better define the allosteric surface responsible for transmitting 
allostery between RAG-1 and RAG-2. In particular, identifying individual residues within RAG-
2(PHDPUNC, group2) that are necessary for rescue of allostery would be insightful. One of the 
limitations of this dissertation is that it only examined residues that differed between M. 
musculus and C. punctatum. It remains possible that residues that are invariant between these 
two species may also play a role in forming this allosteric surface. Future work would need to be 
conducted to identify these residues. However, with the separation of function mutant in hand, 
we could easily further define which residues within group2 are responsible for the rescue of 
allosteric activation.  
This separation of function mutant can be utilized to further define the mechanism behind this 
allosteric activation. It would be interesting to determine which residues of the putative allosteric 
surface, if any, make direct contact with RAG-1. Co-immunoprecipitation experiments utilizing 
our new RAG-2 mutants with RAG-1 could provide much needed mechanistic insight into this 
interaction. It would also be interesting to determine the binding constants for these mutants to 
H3K4me3 utilizing an EMSA. It is possible that restoration of allostery could be affected by the 
strength of binding to H3K4me3.  
We also did not define which residues within RAG-1 may be involved in allosteric transmission. 
It would be interesting to utilize a similar phylogenetic substitution approach with RAG-1 to 
identify residues in RAG-1 that associate with the proposed allosteric surface of RAG-2. Initial 
insights into this could come from computational analyses such as covariation analyses. By 
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examining the co-evolution of residues in RAG-1 and RAG-2, we may be able to isolate patterns 
of co-evolution between the two proteins suggesting a potential interaction of those residues. 
It remains possible that allosteric transmission through a PHD is a more generalizable 
phenomenon. Our insights could provide useful information for how PHDs in general are 
implicated in allostery. Additional experiments utilizing PHD fingers from various species and 
different proteins would be needed to support this hypothesis. 
Overall this dissertation provides new mechanistic insight into how V(D)J recombination is 
regulated at the epigenetic level. Understanding how V(D)J recombination is regulated, in turn, 
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Figure 1.  Association of RAG-2(PHDPUNC) with H3K4me3 in the absence of allosteric 
activation. A, above, representation of M. musculus RAG-2 highlighting the plant 
homeodomain (PHD) sequence in the interval from residue 414 through 485. Below, alignment 
of PHD sequences from C. punctatum and M. musculus.  Residues invariant among all PHD 
sequences are marked in red; residues in C. punctatum that differ from those of the mouse are 
marked in blue.  Conserved residues are indicated by vertical lines; similar residues are indicated 
by vertical dots.  B, above, space filling model of M. musculus RAG-2-PHD finger in complex 
with H3K4me3 peptide (Protein Data Bank ID 2V89). H3K4me3 peptide is indicated in orange, 
residues in M. Musculus that differ from those of C. punctatum are indicated in blue, remaining 
residues are indicated in magenta.  Below, the same structure, rotated 180 ̊ downward. C, binding 
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of RAG-2 and the RAG-2(PHDPUNC) chimera to H3K4me3 peptide. Right, whole cell lysates of 
HEK293T cells expressing full-length, wild-type RAG-2, RAG-2(W453A), RAG-2(PHDPUNC) or 
a fragment of KMT2D, all as MBP fusions, were incubated with bead-bound H3K4me3 peptide. 
Bound protein was detected by immunoblotting. Left, a portion (10%) of each lysate was assayed 
in parallel. D, assay for coupled cleavage. MBP-cRAG-1CT and MBP-RAG-2 or MBP-RAG-
2(PHDPUNC) were copurified and assayed for coupled cleavage of a radiolabeled 12-RSS and an 
unlabeled 23-RSS in the presence of increasing amounts of H3K4me3 or H3K4me0 peptide. 
Accumulation of nicked product at 1 hr is plotted against the concentration of H3K4me0 (pink 
and light blue) or H3K4me3 (red and dark blue).  Wild-type RAG-2 is indicated in pink and red; 
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Figure 2.  Strategy for phylogenetic substitution and back mutation of the RAG-2 PHD.  A, 
RAG-2 variants used in this study. Variants are identified at left. FLAG epitope (FLAG) as well 
as polyhistidine and c-Myc epitopes (His, Myc) are indicated. ID, inhibitory domain. PHD, plant 
homeodomain. PHDPUNC, C. punctatum PHD finger; IDNEUT, inhibitory domain bearing 
neutralizing mutations at acidic residues. Amino acid residues at domain boundaries are 
indicated above and numbered according to the mouse sequence. Positions of point mutations 
introduced into mouse and shark PHD fingers are indicated. AgeI and XhoI restriction sites, 
introduced to facilitate exchange of PHD cassettes, are shown. B, alignment of M. Musculus and 
C. Punctatum PHD sequences. Numbering follows the mouse sequence. Residues that are 
invariant among all PHD sequences are indicated in red; residues in C. Punctatum that differ 
from those in the mouse are indicated in light blue. Clustered mutations that convert residues in 
C. punctatum to the corresponding residues in the mouse PHD are indicated as follows: Group1, 
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dark blue; Group 2, dark purple; Group 3, grey; Group 4, teal; and Group 5, yellow. C, mapping 
of each mutation group onto a space-filling model of the mouse RAG-2 PHD finger in complex 
with H3K4me3. Groups are color-coded as in B. The H3K4me3 peptide is indicated in orange 
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Figure 3.  RAG-2(PHDPUNC, Group1) exhibits normal accumulation but impaired V(D)J 
recombination activity.  A, fluorometric assay for V(D)J recombination. RAG-2 variants were 
transduced into R2K3 cells, selected in puromycin for viral transductants and recombination was 
induced with STI-571; GFP-positive cells were detected by flow cytometry 96 hr after induction. 
IDNEUT, RAG-2(D/E352-405A); IDNEUT, PHDPUNC, RAG-2(D/E352-405A, PHDPUNC); Group 1 
through Group 5, RAG-2(PHDPUNC) variants bearing clustered mutations as defined in Fig. 2B. B, 
Quantified fluorometric assay. GFP-positive cells were counted at 48 and 96 hr after induction. 
Mean (n = 3) and standard deviation are indicated. Control samples were mock-induced with 
water (H2O) as indicated at right. Significance was assessed for 96 hr samples by one-way 
ANOVA and Tukey’s post-hoc test (****, p < 0.0001). C, above, anti-myc immunoblotting of 
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RAG-2 variants in R2K3 lysates at 96 hr after induction.  Images at 5 min and 1 min exposure 
times are displayed.  Below, immunoblotting of actin on the same membrane as above.  Relative 
expression (rel. exp.) was determined by normalizing each anti-myc band in the 1 min exposure 
to the corresponding actin band, followed by normalization to wild-type.  D, the RAG-2 variants 
assayed in A and B were transduced independently in triplicate and assayed in triplicate for 
recombination. The means of the technical triplicates for each biological replicate are plotted. 
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Figure 4.  The Group 2 mutation confers recombination activity on RAG-2(PHDPUNC, Group1). 
A, RAG-2 variants as indicated were assayed for V(D)J recombination in the R2K3 fluorometric 
assay. Displayed are representative flow cytometric data at 96 hr after induction with STI-571. B, 
Flow cytometric data were quantified at 48 and 96 hr after induction. RAG-2 variants are 
indicated below. Control samples were mock-induced with water (H2O) as indicated at right. 
Mean (n = 3) and standard deviation are indicated. Significance was assessed by one- way 
ANOVA and Tukey’s post-hoc test (****, p < 0.0001). C, anti-myc immunoblotting of RAG-2 
variants in R2K3 lysates at 96 hr after induction.  Images at 2 min and 1 min exposure times are 
displayed.  Relative expression (rel. exp.) was determined by normalizing each anti-myc band in 
the 1 min exposure to the corresponding actin band, followed by normalization to wild-type.  D, 
above, assay for binding to H3K4me3.  Lysates of HEK293T cells expressing RAG-2 variants as 
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fusions to MBP (300 µg) were incubated with bead-bound H3K4me0 or H3K4me3 peptide. 
Bound protein was detected by immunoblotting for MBP.  The relative intensity (rel. int.) of 
each band, in comparison to wild-type, is indicated; n.d., not detected.  Below, 50 µl of each 











Supplemental Figure 1.  Extrachromosomal assay for V(D)J recombination.  NIH3T3 cells were 
transfected with the extrachromosomal substrate pJH200, MBP-tagged, full-length RAG-1 and 
MBP-RAG-2-myc-his variants as defined below.  V, transfection with vector in place of RAG-2.  
V(D)J recombination in eukaryotic cells removes a prokaryotic transcriptional stop from pJH200, 
permitting subsequent expression of chloramphenicol acetyltransferase in E. coli. Plasmid DNA 
was recovered at 48 hr and transformed into E. coli.  Transformants were scored for 
chloramphenicol and ampicillin resistance.  The frequency of recombination (chloramphenicol + 
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Supplemental Figure 2.  Accumulation of RAG-2(PHDPUNC) mutant proteins in vivo.  Three 
independent biological replicates, involving independent viral infections, were conducted for the 
R2K3 rearrangement assay. An immunoblot assay corresponding to the first replicate is 
displayed in Fig. 3C; immunoblot assays corresponding to the additional replicates are displayed 
here.  A, above, anti-myc immunoblotting of RAG-2 variants in R2K3 lysates at 96 hr after STI-
571 induction; 5 min and 2 min exposure times are displayed.  Immunoblots correspond to the 
recombination assays indicated in blue in Fig 3D.  Below, immunoblotting for actin on the same 
membrane as above.  Relative expression (rel. exp.) was determined by scanning anti-myc bands 
at 2 min exposure time.  For each band the area under the curve (AUC) was first normalized to 
the corresponding AUC for actin and then to the AUC for wild-type RAG-2.  B, Immunoblots 







Supplemental Figure 3.  Overexpression of RAG-1 fails to enhance accumulation of RAG-
2(PHDPUNC).  RAG-2 constructs were expressed from the pCLIP2a vector while RAG-1 
constructs were expressed from the pcDNA3.1 vector. HEK-293T cells were co-transfected with: 
empty vectors; RAG-1 and pCLIP2a; RAG-2 and pcDNA3.1, RAG-1 and RAG-2; RAG-2 
(PHDPUNC) and pcDNA3.1; or RAG-1 and RAG-2(PHDPUNC).  RAG-1 and RAG-2 variants were 
detected by immunoblotting using an anti-Myc antibody at 24 and 48 hr after transfection.  To 

















































Supplemental Figure 4.  The clustered Group 2 back mutation rescues V(D)J recombination 
activity of RAG-2(PHDPUNC, Group 1).  A, Fluorometric assay for V(D)J recombination in 
R2K3 cells transduced with RAG-2 variants as described in Fig. 3.  Variants were transduced 
using the pCST lentiviral vector, which encodes a Thy1.1 selection marker.  Transduced cells 
were enriched by magnetic bead-based selection for Thy1.1, arrested with STI-571 and assayed 
for inversional V(D)J recombination by flow cytometry at 55 and 94 hr after induction.  
Representative flow cytometric results at 94 hr, gated on GFP+ cells, are displayed.  B, 
Vector WT PHDPUNC































































Quantified fluorometric assay for V(D)J recombination.  Percent GFP-positive cells was 
determined at 55 and 94 hr after induction.  Mean (n = 3) and standard deviation are indicated.  
Significance was assessed for 94 hr samples by one-way ANOVA and Tukey’s post-hoc test 
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Coupled Cleavage Assays. Assays for coupled cleavage of double-stranded oligonucleotide 
substrates HL-44/45 (12-RSS) and HL-46/47 (23-RSS) were performed as described (20), except 
that reactions contained 100nM of RAG tetramer and were preincubated for 30 min in cleavage 
buffer before addition of MgCl2.  
 
Assay for endogenous recombination of immunoglobulin gene segments. The retroviral vector 
pCLIP2a (152) was programmed to express puromycin N-acetyl transferase and FLAG-RAG2-
6His-Myc variants. Viral particles were generated by cotransfection of pCLIP2A constructs and 
pCL-ECO packaging vector into HEK293T cells and concentrated by centrifugation.  R2K3 cells 
were infected by spin inoculation in the presence of 10 µg/mL polybrene.  Cells were maintained 
under selection with 0.8 µg/ml puromycin for 7-9 days.  Recombination was induced in R2K3 
cells (10 ml at 106 cells/ml) by addition of STI-571 to a final concentration of 3 µM for 48 or 96 
hr.   
 
Cell Culture.  Cell lines were propagated at 37° in 5% CO2.  HEK293T cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 1X penicillin-streptomycin-glutamine (PSG).  R2K3 cells (153)were grown in 
RPMI1640 medium supplemented with 10% FBS, 50 µM 2-mercaptoethanol, 1X PSG, 0.7X 
MEM non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES.  R2K3 cells 
containing an integrated PMX-INV recombination substrate (153) were provided by Dr. Barry 
Sleckman (Weill Cornell Medicine)  
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Antibodies.  Commercial antibodies against the following proteins were used in this study: actin 
(clone AC-40, Sigma Aldrich, Cat #A3853); c-myc (clone 9E10, Santa Cruz Biotechnology, 
Cat#sc-40).; MBP (clone N-17, Santa Cruz Biotechnology, Cat#sc-809); histone H3K4me3 
(clone AW304, Millipore Cat#05-791R). 
 
Immunoblotting.  Immunoblotting was performed in PBST (1X PBS, 0.1% Tween) containing 
5% nonfat dry milk.  For immunoblotting, 60 µg of protein was fractionated by 8% SDS-PAGE 
and transferred to a 0.45um PVDF-plus membrane.  Membranes were blocked for 1 hr at 37˚C 
with 5% nonfat dry milk in PBST, incubated with primary antibody for 1 hr at room temperature 
or overnight at 4˚C, washed 3 x 15 min in PBST, incubated with secondary antibody for 1 hr at 
room temperature and washed 3 x 15 minutes in PBST.  Secondary antibody was detected by 
enhanced chemiluminescence (Amersham ECL Prime). 
 
Expression constructs.  DNA fragments encoding full-length wild-type RAG-2 and RAG-
2(W453A), fused in-frame to a cassette encoding an amino-terminal maltose-binding protein 
(MBP) tag followed by a tobacco etch virus (TEV) protease cleavage site (MBP-TEV), were 
cloned between the BamHI and ApaI restriction sites of pcDNA3.1 to produce the plasmids 
pcDNA3.1-MBP-TEV-wtRAG2 and pcDNA3.1-MBP-TEV-RAG2(W453A) (20). To facilitate 
substitution of variant PHD coding sequences for the mouse wild-type PHD coding sequence, 
silent C1242T, A1455T and A1456C mutations were placed within the RAG-2 coding sequence 
of pcDNA3.1-MBP-TEV-wtRAG2 so as to introduce AgeI and XhoI restriction sites at the 
borders of the PHD coding interval.  The resulting plasmid, pcDNA3.1-MBP-TEV-wtRAG2-AX, 
after cleavage with AgeI and XhoI and removal of the wild-type PHD coding sequence, was then 
used as a recipient for synthetic duplex DNA fragments encoding PHD variants ordered as 
gblocks from IDT.  
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The retroviral vector pCLIP2a (54,152) was used for transduction of RAG-2 variants into 
recipient cells.  Sequences encoding wild-type RAG-2 or RAG-2 variants were amplified from 
pcDNA3.1-based vectors by PCR using primers Cla1FLAGRAG2for2019 and 
Mlu1linkerRAG2rev2019.  The resulting amplicons were cloned between the ClaI and MluI 
restriction sites of pCLIP2a to produce viral vectors encoding RAG-2 variants flanked at the 
amino terminus by a FLAG epitope and at the carboxyl terminus by a His6-Myc3 tag. The 
retroviral vector pCST(160,161), encoding the selectable marker Thy1.1, was used in some 
experiments as specified for transduction of RAG-2 variants containing an amino terminal FLAG 
epitope. 
 
The nucleotide sequences of oligonucleotide primers and synthetic duplex DNA fragments used  
in the construction of expression vectors are provided in Supplemental Table 1. 
 
Purification of RAG protein. MBP fusions to full-length RAG-2 variants and an MBP fusion to a 
fragment of RAG-1 spanning amino acid residues 383-1040 (cRAG1-ct) were co-expressed in 
HEK293T cells and purified by amylose affinity chromatography as described (20). Protein 
concentration was determined by 8% SDS-PAGE and Coomassie staining, followed by 
quantification using ImageJ.    
 
H3K4me3 binding assay.  Binding assays were performed as described (6), with modifications.  
Biotinylated peptides derived from histone H3, unmethylated or trimethylated at lysine 4, were 
purchased from Millipore.  HEK293T cells, expressing RAG-2 variants, were lysed in a buffer 
containing 50 mM Tris (pH 7.5), 300 mM NaCl, 1 mM PMSF, 1% NP-40, 1% deoxycholic acid, 
0.1% SDS, and a cocktail of protease inhibitors (Roche). After centrifugation at 16,000 g for 15 
min, aliquots containing 300 µg protein were precleared with 50 μl of a 50% streptavidin agarose 
slurry (Novagen) that had been equilibrated with binding buffer (50 mM Tris [pH 7.5], 300 mM 
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NaCl, 1 mM PMSF and protease inhibitors). Precleared samples were then incubated with 5 µg 
peptide prebound to streptavidin agarose for 4 hr at 4°C. Beads were washed three times with 
binding buffer supplemented with 0.1% NP-40.  Bead-bound protein was released by heating to 
95˚C in SDS-PAGE buffer, fractionated by SDS-PAGE and detected by immunoblotting for 
MBP. 
 
Assay for extrachromosomal recombination.  Assays for recombination of extrachromosomal 
substrates pJH200 (26) were performed as described (17), with modifications.  MBP-RAG-1-
myc-his (10 µg),  MBP-RAG-2-myc-his or RAG-2 variants as indicated in Supplemental Figure 
1  (10 µg) and 4 µg pJH200 (Addgene plasmid #13327) were transfected into NIH3T3 cells 
using the TransIT-LT-1 transfection reagent (Mirus Bio, CAT# MIR2306). At 48 hr post-
transfection, plasmid DNA was recovered by a modified Hirt extraction (Qiagen, CAT #27104). 
DNA (4 µl, about 40 µg) was transformed into 50 µl DH5α Max Efficiency cells (Thermo Fisher, 
Cat #18258012).  A 5 µl aliquot of the transformation mixture was plated on LB agar containing 
50 µg/ml ampicillin and 300 µl was plated on LB agar containing 50 µg/ml ampicillin and 20 
µg/ml chloramphenicol.  Plates containing ampicillin alone were scored after 16 hr at 37˚C, 















Chapter 2: An antigen receptor locus-specific capture sequencing 







V(D)J recombination is catalyzed by the recombination-activating gene protein (RAG) 
recombinase, which consists of RAG-1 and RAG-2 subunits. RAG-induced DNA cleavage is 
constrained to G0/G1 of the cell cycle through the periodic destruction of RAG-2 protein. 
Phosphorylation at RAG-2 T490 leads to the subsequent ubiquitination and degradation of RAG-
2 via the proteasome. The RAG-2 T490A mutation uncouples RAG-mediated DNA cleavage and 
V(D)J recombination from the cell cycle. Against a p53-null background the RAG-2 T490A 
mutation induces lymphoid malignancies characterized by complex chromosomal translocations 
involving antigen receptor loci. To further characterize the genomic rearrangements, present in 
lymphoid tumors from RAG-2(T490A), p53-deficient mice, we developed a capture-sequencing 
method to enrich for genomic rearrangements involving antigen receptor loci. This method is 
capable of identifying endogenous V(D)J rearrangements as well as translocations involving 
immunoglobulin and T cell receptor genes. On a global scale, these tumors are characterized by 










Antigen Receptor Loci Organization 
There are seven antigen receptor loci that encode for B cell receptors (BCRs) and T cell 
receptors (TCRs), immunoglobulin heavy chain (IGH), immunoglobulin light chain lambda 
(IGL), immunoglobulin light chain kappa (IGK), TCRα/δ (TRAD), TCRβ (TRB), and TCRγ 
(TRG). All the loci contain some combination of variable(V), diversity (D), junctional (J) and 
constant (C) gene segments, but the loci differ in the number of gene segments available. Each 
locus has a distinct genomic organization and exhibits differential modes of regulation.  
 
BCRs are comprised of heavy and light chains encoded by the IGH, IGK and IGL loci. The 
murine immunoglobulin heavy chain (IGH) genes are assembled by the joining of VH, DH, and 
JH gene segments that span 2.5Mb of the genome on chromosome 12 (162,163). The IGH locus 
contains 150 VH segments, 10-13 DH segments, 4 JH segments, and 8 CH gene segments. About 
100kb separates the VH segments from the DH gene cluster. The DH cluster is flanked on the 5’ 
end by gene segment DFL16.1 and on the 3’ end by DQ52. DQ52 is less than 1kb upstream of 
the JH cluster. Downstream of the JH cluster lies the Eµ intronic enhancer and the exons encoding 
Cµ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, and Cα. Further downstream of Cα is the 3’ regulatory 
region(162). In contrast to IgH, the IGK and IGL loci contain only V and J gene segments. For 
example, IGK is on mouse chromosome 6 and contains 96 function VK segments, which span 
3.2Mb,  4 JK segments, and CK(163).  
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TCRs are comprised of either α and β chains or γ and δ chains. The TRG is the smallest TCR 
locus, spanning less than 200kb, while the TRAD locus spans over 1Mb(164). TRG has four 
copies of the V-J-C gene segment cassette. The TRAD locus is comprised of the TCRδ (TRD) 
locus embedded within the TCRα (TRA) locus on chromosome 14. This locus contains 104 V 
segments, which can rearrange to two Dδ and Jδ segments or to 61 Jα segments (163). The TRB 
locus spans 700kb on chromosome 6 and contains 35 Vβ segments upstream of a duplicated 
cluster, each containing 1 Dβ segment, 7 Jβ segments, and a set of Cβ exons. These clusters are 
termed TRβ1 and TRβ2.  
 
B cell development 
B cells originate in the bone marrow from lymphoid progenitors derived from hematopoietic 
stem cells, mature in the bone marrow, and eventually move to the spleen and secondary 
lymphoid tissues.  The IGH locus is the first to undergo rearrangement. These gene segments are 
rearranged in an ordered fashion beginning with D-to-JH rearrangements, followed by VH-to-DJH 
rearrangements until a productive rearrangement is created (113). B cells transition from early 
pro-B cells which undergo D-to-JH rearrangement, to late pro-B cells which undergo VH-to-DJH 
rearrangement, to large pre-B cells that contain a completed V(D)JH rearrangement, to small-
preB cells which undergo VL-to-JL rearrangement, to immature B cells containing a fully 
rearranged heavy and light chains. At the pro-B and pre-B stages, B cells express a surrogate 
light chain which associates with the heavy chain forming a pre-B cell receptor complex on the 
surface of the cell until the IGK or IGL light chain locus is productively rearranged(165,166). 
The pre-BCR induces proliferative expansion of pre-B cells, downregulation of the surrogate 
light chain, and downregulation of RAG-1 and RAG-2 transcription(166). Upon successful light 
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chain gene rearrangement, a naive B cell is formed and is ready to encounter antigen. While in 
the bone marrow, B cells undergo positive selection to select for cells that can recognize ligand 
and signal properly. B cells then proceed through negative selection in which self-reactive B 
cells either are clonally deleted through apoptosis(167-169) or undergo another round of V-to-J 
light chain gene recombination, termed receptor editing, to eliminate self-reactivity(170). After 
selection, B cells then migrate to the spleen and differentiate into mature naïve B cells. 
 
Cells must encounter antigen in order to become activated. These interactions with antigen occur 
predominantly in secondary lymphoid tissues such as the spleen, lymph nodes, and Peyer’s 
patches. These tissues are specialized to filter body fluids, to capture and display foreign antigens 
for B cell recognition, and to recruit lymphocytes from the blood. Within a lymphoid follicle, 
follicular dendritic cells can capture and display opsonized antigens. These antigens can be 
displayed to B cells and activate B cell receptors (BCRs). Signaling through the BCR, with the 
help of co-receptor activation, T cell help, and/or cytokine signals initiates B cell activation(171). 
Activation can be T cell dependent or independent. The BCR and bound antigen is then 
internalized, antigen is enzymatically processed, and antigenic peptides are displayed on MHC 
class II for presentation to T cells.  
 
After activation depending on the signals, B cells can differentiate to form germinal center B 
cells, plasma cells, memory B cells, or mature B cells(171). B cells that become germinal center 
B cells can undergo affinity maturation, somatic hypermutation by AID, and selection within the 
germinal center. B cells that are differentiating into plasma cells and still actively proliferating 
are called plasmablasts, but upon the cessation of proliferation they become plasma 
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cells/antibody secreting cells. Memory B cells can be reactivated by subsequent antigen 
exposures and are poised to rapidly differentiate. Upon re-exposure to antigen, memory B cells 
may undergo class switch recombination to change the isotype of the BCR from IgM and IgD to 
IgG, IgA, or IgE (171).   
 
T cell development 
T cells develop from lymphoid progenitors which originate from bone marrow progenitors and 
then migrate to the thymus where they undergo maturation, selection, and export to peripheral 
tissues. T cells begin as CD4-CD8- double negative (DN), become CD4+CD8+ double positive 
(DP), and then finally become CD4+ CD8- or CD4-CD8+ single positive (SP). Within the thymus, 
T cells undergo T cell receptor (TCR) rearrangement to eventually generate CD4+CD8+ double 
positive thymocytes. TCRs are encoded within the TRAD, TRB, and TRG loci. Recombination 
of the TRG, TRB, and TRD loci all occur during the double negative stages of thymocyte 
development. The two possible types of TCR are γδ TCR and αβ TCRs. Productive 
rearrangement of TRG and TRD results in expression of a γδ TCR, whereas successful 
rearrangement of TRB leads to a pre-TCR comprised of TCRβ with a pre-TCRα (172). The pre-
TCR can signal to downregulate RAG expression, increase proliferation, mediate β chain allelic 
exclusion, and differentiation toward the DP thymocyte stage. At the DP stage RAG is re-
expressed and TRA rearrangement begins.  
 
Each locus is controlled and recombined differently. TRG rearrangement is dependent on IL-7 
signaling (172). IL-7 activates STAT5 which can bind to Jγ promoters and 3’Eγ enhancer.  
Recombination at TRB is developmentally controlled, with Dβ-to-Jβ recombination preceding 
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Vβ-to-DβJβ recombination. This control is dependent on the Eβ enhancer and the nature of the 
RSSs(172). The Vβ-to-DJβ rearrangement is subject to allelic exclusion, so that T cells only 
express one function TRB gene. This is enforced through feedback inhibition established by pre-
TCR signaling. The TRAD locus consists of the TRD locus embedded within the TRA locus. 
Vδ-toDδ-toJδ recombination occurs in DN T cells, whereas Vα-to-Jα recombination occurs in 
DP T cells(172). This developmental control is enforced through the differential activation of 
developmental stage specific enhancers.  
 
Within the thymus, DP thymocytes undergo positive selection based on the ability to interact 
with MHC-I or MHC-II. This ensures the T cells have the ability to recognize MHC molecules. 
Cells that can properly respond to MHC-I or MHC-II receive survival signals while those that do 
not interact well will die. Next a thymocyte undergoes negative selection, or clonal deletion, to 
remove self-reactive clones. Thymocytes that interact strongly with self-antigens die by 
apoptosis, but some survive as regulatory T cells (Tregs). Tregs are beyond the scope of this 
dissertation and will not be covered in detail. Cells that survive positive and negative selection 
then exit the thymus as mature naïve T cells.  
 
Naïve T cells encounter antigens and costimulatory ligands presented by dendritic cells. This 
activation requires engagement of the TCR and a costimulatory molecule by MHC-II and MHC-I 
for CD4+ and CD8+ T cells respectively, and results in IL-2 production, proliferation, and 
differentiation into effector cells that migrate to various sites and engage in pathogen clearance. 
The majority of effector T cells apoptose following infection, but a subset of T cells persists as 
long-term memory cells that can protect against a subsequent infection. Beyond activation, T 
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cells can further differentiate into various types of memory T cells such as stem cell memory, 
central memory, and effector memory T cells. These developmental stages are beyond the scope 
of this dissertation and will not be explored further.  
 
Temporal regulation of V(D)J recombination 
V(D)J recombination is restricted to the G0/G1 phase of the cell cycle through the periodic 
degradation of RAG-2(61). RAG-2 is phosphorylated at T490 by CyclinA/CDK2 at the G1-to-S 
transition leading to subsequent ubiquitylation by the Skp2-SCF ubiquitin ligase, followed by 
proteasomal degradation(57-60). By limiting the formation of RAG-mediated DNA DSBs to 
G0/G1, the resulting DNA ends are sequestered from homologous recombination and repaired by 
NHEJ which predominates during G0/G1. This coupling of V(D)J recombination to the cell 
cycle suppresses genomic instability and lymphoid tumorigenesis(62). Mutation of the T490 
phosphorylation site to alanine permits RAG-2 expression throughout the cell cycle(62). This 
constitutive RAG expression leads to accumulation of DNA DSB throughout the cell cycle and 
exposes DNA ends to both NHEJ and homologous recombination machinery. The mouse model 
employed in this dissertation contains the T490A mutation crossed into a p53 deficient 
background. These mice exhibit complex chromosomal translocations involving the antigen 
receptor loci(62). 
 
Spatial regulation of V(D)J recombination 
Three-dimensional genome organization and spatial proximity can influence genome wide 
chromosomal rearrangements and translocations(173). Through the use of genome-wide 
chromatin conformation capture using proximity ligation (Hi-C), mouse chromosomes with close 
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spatial proximity in the nucleus were found to correlate with increased participation in 
translocations(173). Additionally, spatial organization appears to be similar between 
species(173). For example, the frequency of IgH, IgK or IgG to c-myc translocations in Burkitt’s 
lymphoma is positively correlated with the reciprocal nuclear distance between each loci(174). 
 
In addition to nuclear proximity, synapsis of antigen receptor gene segments is required for 
cleavage by RAG. These segments span large regions of the genome. In the RSS capture model, 
RAG binds one RSS and then captures a second RSS to form the synaptic complex. V-to-DJ 
recombination requires conformational changes within the antigen receptor locus to reduce the 
distance between the V gene segments and the DJ segment. Chromatin looping can bring 
together distant gene segments. Chromatin looping mediated by the CCCTC binding factor 
(CTCF) has been implicated in the regulation of V(D)J recombination(175). CTCF is a 
transcription factor containing 11 zinc-finger domains that bind to many sites in the mammalian 
genome and is enriched at antigen receptor loci(118). The murine IgH locus spans 2.7Mb, so that 
locus contraction and looping are needed to aid in rearrangement. There are 144 putative CTCF-
binding sites within the IgH locus which appear to be evolutionarily conserved and exhibit a 
strand-orientation bias with respect to VH gene transcription(176).  
 
Through the introduction of bait RAG-generated breaks, it was found that RAG “off-target” 
breaks, occurring at the CAC motif of cryptic RSSs, are largely confined to convergent, CTCF-
binding element (CBE)-flanked domains containing the bait RSS pair(177). This observation is 
consistent with linear tracking of RAG along chromatin within a loop(177).  VH-associated CBEs 
appear to also play a role in VH gene segment utilization(178). 
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CTCF-mediated looping can also regulate RSS availability, enhancer activation, and directional 
tracking of RAG along chromatin(118). Experiments involving introduction of ectopic CBEs at 
the TRAD locus demonstrated that CTCF is able to regulate V(D)J recombination by preventing 
RSS synapsis through the separation of RSSs into discrete loop domains(118). This effect was 
independent of transcription and RSS accessibility (118). 
 
A key regulatory region, the intergenic control region 1 (IGCR1) resides between the VH and DH 
clusters of the IgH locus. IGCR1 plays a role in B cell development, suppresses activation of 
germline VH segments, balances proximal versus distal VH segment use, and is required for 
lineage specific VH-to-DJH recombination (179). These functions of IGCR1 are dependent on 
CTCF-binding elements CBE1 and CBE2, although individual deletions of CBE1 or CBE2 
produce only slight impairment of function, suggesting cooperative activity(180). Higher order 
looping can allow gene loci to migrate further away from their respective chromosome territory 
within the nucleus. Data revealing looping of the TRA locus suggests that higher order DNA 
looping can help direct RAG to specific loci(181,182).  
 
Oncogenic genomic aberrations and V(D)J recombination 
Many human cancers, including leukemias and lymphomas, are characterized by genomic 
rearrangements such as translocations. Oftentimes, these translocations are insufficient on their 
own to cause malignancies but serve as initiating events, after which secondary mutations can 
drive development of cancer. For example, in acute lymphoblastic leukemia (ALL) 25% of cases 
contain the ETV6-RUNX1 fusion protein(56). Additional somatic mutations are required for 
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development of overt leukemia.  RAG-mediated recombination is the dominant mutational 
process that promotes development of ETV6-RUNX1-positive pre-B-ALL(56).  
 
Genomic rearrangements are initiated by DNA double stranded breaks (DSBs) which can arise 
physiologically or by genotoxic insult. To generate a translocation, two DSB must be present 
simultaneously at the two participating loci, the loci must be in proximity or move into proximity, 
and DNA DSB repair must be available to join the broken DNA into a translocation(183). The 
two major sources of physiological DSBs in B cells are V(D)J recombination and class switch 
recombination. Improper repair of these physiological DSBs can lead to genomic rearrangements 
such as translocations. The origins of translocations can be attributed to recurrent DNA damage, 
frequent nuclear interactions, and random rearrangements(184). Additionally, the mode of DSB 
repair can also directly contribute to genomic abnormalities. In particular, lymphoid 
malignancies are often characterized by recurrent chromosomal rearrangements involving the 
activation of oncogenes(183). This commonly results from the generation of an oncogenic fusion 
protein or by deregulating oncogene expression by linking it to strong transcriptional elements of 
an antigen receptor locus(30,183,185).  
 
Aberrant V(D)J recombination can be carcinogenic either through creation of off-target DSB or 
through the creation of DNA by-products. In addition to the coding joint formation, V(D)J 
recombination creates a signal joint comprised of the two RSSs and the intervening DNA 
fragment. Initial work demonstrated that RAG is capable of acting on these signal joints in vitro 
and subsequent studies showed RAG can support their transposition in the genome(186,187). 
Investigation of the ability of RAG to perform intermolecular recombination between two 
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plasmids led to proposal of a release and capture model in which coding ends are released from 
the post-cleavage complex and then recaptured by RAG(188). In vitro, RAG can cleave plasmid 
substrates both in cis and in trans. V(D)J recombination in trans has potential to lead to 
chromosomal rearrangements and genomic instability. One line of evidence implicating V(D)J 
recombination in genome instability came from detection of V(D)J recombination by-products in 
mouse thymocytes and their ability to be reintegrated into the genome(187,189).  RAG exhibits a 
preference for GC rich DNA at the site of transposition(190). Episome-based assays 
demonstrated that RAG proteins can perform transposition in vivo, but at a low frequency(191). 
Interestingly, this work also revealed aberrant events in which the signal end fragment was 
integrated in the genome and accompanied by large scale deletions or translocations(191). 
Modes of regulation restricting these transposition events were discussed in Chapter 1 under the 
evolution of RAG-1 and RAG-2.  
 
Three major types of translocations have been identified. The first is termed a type I 
translocation and involves illegitimate V(D)J recombination between a legitimate Ig/TCR gene 
segment and an illegitimate proto-oncogene locus. These translocations result from mis-targeting 
of RAG. Type II translocations involve legitimate Ig/TCR gene segment breaks, and DSB within 
a proto-oncogene generated by another mechanism. Type II translocations thus involve three 
DSBs, two at Ig/TCR segments and one at a proto-oncogene and result from mistakes in repair of 
the V(D)J intermediates. Type III translocations involve both targeting and repair mistakes by 
RAG and the repair machinery(192).  
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Off target V(D)J Recombination 
V(D)J recombination can catalyze both DNA transposition and translocation in vitro and in vivo. 
Many lymphoid malignancies are characterized by chromosomal translocations involving 
antigen receptor genes and proto-oncogene loci, suggesting that these rearrangements could be 
RAG mediated(56). Many of these translocations can be attributed to off target RAG activity on 
genomic DNA containing cryptic RSS-like elements(193). Cryptic RSSs resemble an RSS, and 
are estimated to be present once every 600bp in the genome(194). Rearrangements involving 
cRSS can lead to oncogenic translocations and deletions(183,195-197) A canonical RSS consist 
of a heptamer (5’-CACAGTG) and a nonamer (5’ACAAAAACC) separated by either a 12 or 
23bp spacer. Heptamers are cleaved by RAG 5’ to the CAC motif, whereas the nonamer serves 
as a binding site for RAG-1. Single base-pair changes to an RSS can affect recombination. For 
example, mutation of the perfectly conserved third position of the heptamer blocks 
cleavage(198).  
 
The C-terminus of RAG-2 is important for restricting off-target recombination. Mice deficient in 
p53 but expressing core-RAG-2 develop thymic lymphomas and exhibit more off-target 
rearrangements than their control p53 deficient counterparts(199,200). These core-RAG-2 p53 
deficient mice also exhibit translocations between TRAD and IgH loci. These phenotypes are 
similar to those observed in the lymphomas of ATM deficient mice, suggesting that similar to 
ATM deficiency, core RAG-2 destabilizes the RAG post-cleavage complex(200). Since these 
breaks are not programmed to occur within the same lineage or the same cell, it was of interest to 
determine the mechanism underlying this translocation type. Nuclear accessibility of the TRAD 
and IgH loci increases in the absence of DNA repair factor ATM or the absence of the RAG-2 
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non-core(201). Translocations involving LMO2, TAL1, Ttg-1, and Hox11 have been 
documented as examples of illegitimate V(D)J recombination at cRSS sites emphasizing the 
importance of understanding potential off target V(D)J recombination in order to maintain 
genome integrity(202). 
 
 One mechanism of protection against these off-target recombination events has been the 
evolutionary depletion of cRSSs, specifically heptamer sequences, near RAG-1 binding 
sites(147). In particular by utilizing a ligation-mediated transferred-end capture assay which 
detects insertions of RSS-ended DNA fragments into the genome, core-RAG-2 thymocytes show 
a higher frequency of off target events at cryptic RSSs than wildtype mice, implicating the non-
core region of RAG-2 in maintaining the integrity of the genome(193). 
 
Another mechanism of protection from genomic instability involves the heptamer sequence and 
the stability of the post-cleavage complex containing RAG and the signal ends. After cleavage, 
RAG remains bound to the signal ends more tightly than the coding ends(203). Foot printing 
analyses revealed that this binding is dependent upon interactions between RAG and the 
heptamer sequences of the RSSs(203). Mutations that destabilize the signal-end complex in vitro 
allowed coding and signal ends to be repaired by inappropriate DNA double strand break repair 
pathways, such as alternative NHEJ, which is explained in further detail in the next section. Non-
consensus heptamer sequences can destabilize the post-cleavage complex and allow for aberrant 
repair of DNA ends, potentially leading to genomic instability(203). 
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Double strand break repair of V(D)J recombination cleavage products 
In addition to off-target RAG activity, the repair of DNA DSBs can also lead to genomic 
rearrangements. Unrepaired breaks that persist throughout a cell’s development can lead to 
rearrangements between loci that usually are not accessible at the same time. Beyond the failure 
of break repair, the actual repair process itself can cause genomic rearrangements. There are 
three main pathways for repairing DSBs in mammalian cells, classical NHEJ (cNHEJ), 
alternative NHEJ (altNHEJ), and homologous recombination (HR)(87). cNHEJ factors are 
implicated in maintaining genomic integrity at the genome scale and is not considered to be a 
major error prone process. Artemis is an cNHEJ factor with both endo and exonuclease activity. 
During V(D)J recombination, Artemis opens the hairpins at coding ends. In Artemis-deficient 
murine embryonic stem cells, V(D)J coding joins lack deletions and display large palindromic 
insertions suggesting a hairpin opening defect(204). They also exhibit increased chromosomal 
instability which includes telomeric fusions. Deficiencies in cNHEJ factors on a p53-deficient 
background promote development of pro-B cell lymphomas characterized by oncogenic 
chromosomal translocations involving the IgH and c-Myc loci (85). These translocations exhibit 
microhomologies at the breakpoints suggestive of DNA double strand break repair by altNHEJ. 
 
The V(D)J recombinase plays a role in directing which mode of repair occurs after cleavage. 
After cleavage, RAG retains association with the coding and signal ends in a post-cleavage 
complex, which is important for proper cNHEJ. Mice harboring a RAG-1 hypomorphic mutation 
S723C, which can catalyze cleavage but is defective in post-cleavage complex formation, exhibit 
aberrant DSB formation and predisposition toward chromosomal translocations in a p53-
deficient background(107). Additionally non-consensus heptamer motifs, including a subset of 
	 67 
cryptic RSSs, can destabilize the post-cleavage complex and allow the DNA ends to be repaired 
by altNHEJ(203,205). This suggests a role for the RSS sequence in maintaining genomic 
stability.  The C terminus of RAG-2 is important for proper DSB repair. Deletion the C-terminus 
allows altNHEJ to repair DSB in both cNHEJ proficient and cNHEJ deficient mice(206). 
altNHEJ is characterized by extensive end resection, junctional microhomolgies and 
translocations(85). Further support for the role the RAG-2 C-terminus in DSB repair pathways 
choice came from studies utilizing RAG-2 C terminal truncation mutants, which exhibited robust 
alternative end joining(207).  
 
To limit DSBs at multiple loci within development, developing lymphocytes utilize a DNA 
damage response that suppresses RAG-1 and RAG-2 expression upon detection of a DSB(208). 
Furthermore, DSBs can initiate an ATM dependent DNA damage repair pathway which causes 
RAG-2 to relocalize outside of the nucleus to centrosomes(209). The RAG-2 core is sufficient 
for this export, and mutation of T490 prevents this nuclear export(209). 
 
Class switch recombination represents another source of programmed DNA DSB at the IGH 
locus. This process translocates productive VDJ exons from their initial positions upstream of 
Cµ and Cδ to positions upstream of the γ, α or ε exons. Recombination involves formation of 
DNA DSB within a pair of IGH switch regions. These breaks are repaired by the cNHEJ 
machinery. Deficiencies in DNA double strand break repair factors are associated with 
translocations of c-myc to switch region junctions and increased usage of altNHEJ as evident 
from junctional microhomology(210). Thus, DSB associated with CSR may be joined with to an 
aberrant RAG-induced DSB to form a translocation(210). 
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Recurrent translocations in lymphoid malignancies 
Balanced chromosomal translocations involving the Ig loci and oncogenes are frequently 
observed in B cell lymphomas. B cell development involves multiple processes that subject Ig 
genes to DNA cleavage such as V(D)J recombination, somatic hypermutation, and class switch 
recombination. DSB generated within Ig loci by these processes are then susceptible to fusion 
with other DSB produced within oncogenes. In humans, recurrent RAG-mediated translocations 
have been proposed to include the chr8:14 translocation involving IgH and c-myc in Burkitt 
lymphoma, the chr11;14 translocation involving IgH and bcl-1 found in mantle cell lymphomas, 
the chr14:18 translocation involving IgH and bcl-2 in follicular lymphoma and the chr1:14 
translocation involving IgH and bcl-10 found in mucosa-associated lymphoid tissue(MALT) 
lymphoma(183). A frequently observed translocation involves the switch regions of IgH and the 
c-myc gene(211). These Ig:Myc translocations can arise from activation-induced cytidine 
deaminase (AID) dependent and independent mechanisms(211).  A similar translocation between 
IgH and sequences downstream of c-myc is observed in B cell lymphomas from ATM deficient 
mice(212). This work suggested a role for ATM in preventing the formation of chromosome 12 
dicentrics via recombination between IgH DSB and breaks downstream of c-myc(212). The 
frequent occurrence of B lymphoid tumors harboring c-myc translocations has suggested 
preferential rearrangement with c-myc. By replacing the c-myc coding sequence with n-myc, Alt 
and colleagues demonstrated that there are features of the c-myc locus that make it a preferred 
translocation target(213). Within the IgH locus, the regulatory region (IgH3’RR) is important for 





With the rise of the genomics era, sequencing methodologies have assumed a central role in the 
analysis of biological phenomena. Detecting and quantifying genomic double stranded breaks 
(DSBs) has been a challenge, but much progress has been made because of advancements in 
sequencing technology. Analyses of short read paired-end sequences present many challenges in 
the analysis of cancer genomes. Roth and colleagues developed a method to identify tumor-
specific structural variants that was designed to reduce false positives(215). They applied this 
method to analyzing a core RAG-2, p53 deficient mouse and were able to identify specific 
rearrangements with support of as few as 2 independent read pairs(215). 
 
Alt and coworkers have developed a high-throughput, genome-wide translocation sequencing 
method, HTGTS, capable of identifying genome-wide translocation junctions arising from a 
specific cellular DSB created by the I-Sce1 meganuclease.(185).  This method permits 
identification of other genomic DSB that are capable of joining to the test DSB. To test this 
method, DSB were created in the c-myc and IgH loci in activated B cells. The majority of 
translocations were intrachromosomal and frequently fell near transcription start sites 
(TSS)(185,216). The method was then expanded to other sources of programmed DSBs, such as 
Cas9 or TALENs, which provided useful data regarding off-target cutting by these engineered 
nucleases(217). Using RAG-generated breaks as bait, this technology was able to identify a large 
number of RAG “off-target” cleavage events(177).  
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A variety of methods, such as BLESS(218),  have been developed to detect DSB, but most have 
only been efficacious in cell lines. Recently, Sleckman and colleagues developed sequencing 
methodologies, initially HCoDES and later END-Seq, that are capable of identifying DSB within 
the genome both in cell culture and in vivo(219,220). These methods utilize hairpin adapters 
followed by a pulldown to identify precise locations within the genome containing DSBs. This 




To characterize genomic rearrangements associated with mistimed V(D)J recombination in vivo, 
we employed a mouse model carrying the RAG-2 T490A mutation, which ablates the 
cyclinA/cdk2 phosphorylation site that triggers RAG-2 degradation at the G1-to-S transition.  
Expression of the RAG-2(T490A) mutant protein persists throughout the cell cycle. To reveal 
potential oncogenic effects, we the RAG-2T490A allele onto a p53-deficient background(62). Of 
particular note, the T490A mutation is dominant.  
 
We employ the RAG-2(T490A) p53-deficient mouse model of mistimed V(D)J recombination to 
(1) identify aberrant V(D)J recombination events in vivo, and (2) identify translocation partners 
involved in chromosomal rearrangements involving an antigen receptor locus. We developed a 
targeted method, based on the approach of Halper-Stromberg et al. (221), to selectively sequence 
V(D)J recombination events in this model (221). Several technologies exist to detect 
translocations within the genome. Of relevance, high throughput genomic translocation 
sequencing (HTGTS) is capable of detecting translocation partners by following a specific 
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targeted ‘bait’ double stranded break (185). Our technology has the advantage of being able to 
capture spontaneous RAG generated DSB within the genome and the following translocation 
partner in an unbiased fashion. We demonstrate that this method can detect canonical V(D)J 






Characterization of lymphoid tumors from mice bearing the dominant RAG-2(T490A) mutation 
on a p53-deficient background.   
 Previous work from this laboratory demonstrated that RAG-2(T490A) is oncogenic in the 
B and T lymphoid lineages when expressed on a p53-null background (62).  With respect to the 
malignant phenotype RAG-2(T490A) is dominant, with no apparent differences between mice 
that are heterozygous or homozygous with respect to the RAG-2(T490A) allele (62).  Spectral 
karyotypic analysis and fluorescence in situ hybridization revealed that lymphoid malignancies 
arising in RAG-2(T490A), p53-null mice exhibit complex chromosomal translocations involving 
antigen receptor loci (62).  Here we employ hybridization-based capture sequencing to 
characterize genomic structural variants in these lymphoid malignancies at single-nucleotide 
resolution.  
 We began by collecting lymphoid tumors from p53-deficient mice homozygous or 
heterozygous for the RAG-2(T490A) allele (RAG-2T490A/+Trp53-/- or RAG-2T490A/T490ATrp53-/-) 
and from p53-deficient control mice homozygous for the floxed, wild-type RAG-2 allele (RAG-
2fl/flTrp53-/-).  .  Among all three genotypes, from 70%  percent of mice developed tumors by 24 
weeks of age, with an average age of 23 weeks upon euthanization.  Tumors were dispersed and 
the distributions of cell size and granularity were determined by flow cytometry; lymphoma cells 
exhibited increased size and granularity with respect to normal lymphocytes.  Lymphomas were 
assayed for expression of the B and T lineage markers B220 and CD3, respectively (Fig. 1A).  
CD3+, T lineage tumors were further assessed for surface expression of CD4 and CD8 (Fig. 1A).  
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Of the 45 RAG-2T490A/+ Trp53-/- and RAG-2T490A/T490ATrp53-/- mice analyzed, more than 82 
percent developed splenic or thymic tumors (Fig. 1B).  In about 18 percent of the RAG-2T490A/+ 
Trp53-/- and RAG-2T490A/T490ATrp53-/-  mice tumors arose in sites other than thymus or spleen, in 
contrast to RAG-2fl/flTrp53-/- mice, in which more than 36 percent of tumors involved non-
lymphoid organs, defined as not arising from the spleen or thymus and not expressing T or B 
lineage markers.  Excluding mice without lineage information, about 74 and 72 percent of 
tumors arising in RAG-2(T490A), p53-null and wild-type RAG-2, p53 null mice were of the T 
lineage respectively (Fig1C). B lymphoid tumors were exclusively found in RAG-2(T490A), 
p53-null animals (Fig1C), consistent with previous results (62).  
 
Capture sequencing strategy and probe design 
 By spectral karyotyping and fluorescence in situ hybridization it was previously shown 
that uncoupling of V(D)J recombination from the cell cycle is associated with chromosomal 
translocations involving antigen receptor loci.  The resolution of these earlier studies, however, 
was too low to provide information regarding the mechanisms by which these translocations 
were formed.  To define the corresponding recombinant junctions at the nucleotide sequence 
level we employed a capture sequencing strategy.  To identify structural rearrangements that 
involved antigen receptor loci, we designed RNA capture probes across a selection of the antigen 
receptor loci. Of the seven murine antigen receptor loci , IGH, IGL, IGK, TRB, TRAD and TRG, 
we included IGH, TRB, and TRAD in the analyses because (1) translocations involving IGH and 
TRAD were previously detected in lymphoid tumors from RAG-2(T490A), p53-null mice and (2) 
the TRB locus is developmentally analogous to IGH.  The IGH and TRB capture regions 
spanned the genomic intervals 114666978-114720181 on chromosome 12 and 41483000-
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4158570 on chromosome 6, respectively, which included the D and J clusters of each locus.  The 
TRAD capture region included the interval 54732943-54844073 on chromosome 14, spanning 
the Dδ and Jδ clusters, Cδ, the Jα cluster and Cα. The larger intervals spanning the V segments at 
each locus were excluded, as their presence would greatly increase the size of the capture region, 
thereby limiting the depth of sequencing.  Consequently, we were unable to detect non-canonical 
V segment rearrangements except for those involving recombination partners within the capture 
intervals.  
 Two probe sets were constructed, a combined IGH/TRB probe set and a TRAD probe set. 
Probes were arrayed at five-fold tiling so that each nucleotide within the capture regions was 
capable of hybridizing to five different probes (Fig. 2A).  Because the antigen receptor loci 
contain repetitive elements in the form of gene segments and recombination signal sequences, we 
did not perform repeat-masking when designing these probes.  
 
Sequence analysis pipeline 
 To identify genomic rearrangements involving the capture regions we performed hybrid 
capture and paired end Illumina sequencing; reads were analyzed according to the pipeline 
outlined in Fig. 2B.  Using the TRAD probe set for enrichment, we analyzed 16 tumors from 
RAG-2T490A/+ Trp53-/- or RAG-2T490A/T490ATrp53-/- mice, 1 tumor from a RAG-2fl/+Trp53-/-  and 1 
tumor from a RAG-2+/+ Trp53-/- mouse (Table 1).   Using the IGH/TRB probe set, we analyzed 6 
tumors from RAG-2T490A/+ Trp53-/- or RAG-2T490A/T490ATrp53-/- mice (Table 1).  An average of 
13.5M reads were obtained from each tumor sample using the TRAD probe set.  Reads were 
aligned to the reference mouse genome, mm9, using the short read aligner BWA-MEM(222). On 
average, 90.3% of reads mapped to the capture region, indicating efficient enrichment by hybrid 
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capture.  We then took the set of all paired reads and used samtools (223)  to remove those in 
which the paired reads mapped in a proper pair, thereby enriching for paired reads spanning 
recombinant junctions.  After removal of properly paired reads we obtained about 1.75M reads 
from each tumor, or about 12% of each original dataset; these were mapped to the reference 
genome.  After mapping, split and discordant reads were extracted using samblaster (224) and 
examined using the Integrative Genomics Viewer (IGV) (225-227).  Once in IGV we scanned 
for the occurrence of sequence pileups spanning putative recombinant junctions.  We then 
proceeded to verify recombination events by PCR and Sanger sequencing, as described below; as 
few as two split reads were sufficient to identify verifiable rearrangements.   
 
Canonical V(D)J recombination events 
 We expected to find products of canonical V(D)J rearrangement among the recombinant 
junctions mapped by the procedure described above.  Examination of split and discordant reads 
identified 18 pileups consistent with canonical V(D)J recombination events. We characterized 
one such V(D)J rearrangement, VH3.8-DSP2-JH1, obtained from a B lymphoid lymphoma 
arising in a RAG-2T490A/T490ATrp53-/- mouse using the IgH/TRB probe set.  The genomic 
rearrangement was represented by one pair of discordant reads and three split reads (Fig. 3A).  
The presence of this rearrangement was verified by PCR amplification with primers specific for 
the VH3.8 and JH1 gene segments, followed by Sanger sequencing (Fig. 3B).  The split read 
sequence was evidently the product of a VH3.8-to-DSP2-to-JH1 rearrangement; the sequence 
interposed between the VH and JH segments is consistent with use of DSP2.3, DSP2.4 or DSP2.6 (Fig. 
3C).  Non-templated insertions were detected at the VH-to-D and D-to-JH junctions, as is typical 




 Having established that the capture sequencing protocol was able to detect canonical 
V(D)J recombination events, we proceeded to look for translocations involving the capture 
regions.  The sequence analysis pipeline described above identified 575 putative genomic 
rearrangements among all tumors analyzed; of these 481 were consistent with interchromosomal 
translocations.  One of these, a t(14:16) translocation involving the TCRA locus and the 
Roundabout Guidance Receptor 2 (Robo2) gene, was obtained from a T lymphoid tumor arising 
in a RAG-2T490A/T490ATrp53-/- mouse using the TRAD probe set (Fig. 4A).  Robo2 encodes a 
transmembrane receptor for the repulsive guidance protein Slit2 and is implicated in axon 
guidance and cell migration(228).  This translocation, which was represented by 3 discordant 
read pairs and 6 split reads (Fig. 4A), was verified by PCR (Fig. 4B) and by Sanger sequencing 
(Fig. 4C). The chromosomal breakpoints at the translocation junction reside in the 5' flank of the 
TRAJ49 gene segment and the intron between exons 3 and 4 of Robo2 (Fig. 4C).  The TRAJ49 
breakpoint lies within the nonamer of the 5' flanking RSS, consistent with RAG-mediated 
cleavage at the nonamer-distal end of the heptamer, followed by partial resection of the resulting 
signal end.  of TRAJ49.  While deletion of nucleotides from signal ends is rare in physiologic 
V(D)J recombination, the resection of the signal end seen in this instance is in agreement with 
our previous finding that the RAG-2(T490A) mutation is associated with an increase in the 
frequency of nucleotide loss at RSS signal junctions(62).  Within the Robo2 gene, the breakpoint 
is unaccompanied by a nearby cryptic RSS.  No microhomology was observed at the junction, 
consistent with repair by classical NHEJ.  We did not detect this translocation in any of the other 
tumors analyzed.  
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 A t(12;15) translocation was obtained from a B lymphoid tumor arising in a RAG-
2T490A/T490ATrp53-/-  mouse using the IGH/TRB probe set (Fig. 4D). This rearrangement is 
documented by 5 split reads. One breakpoint lies between the Cδ and Cγ3 exons in the IGH 
locus on chromosome 12; resides 744kb downstream Myc and 358 kb downstream of Pvt1 on 
chromosome 15. This rearrangement places Myc and Pvt1 downstream of the IgH D constant 
region, in a transcriptionally convergent orientation. The translocation was verified by PCR and 
Sanger sequencing (Fig. 4E and F).  The breakpoint on chromosome 15 is apparently 
unaccompanied by a cryptic RSS, while the breakpoint on chromosome 12 is flanked by a nearly 
canonical RSS (Fig 4F).  The structure of the chromosome 12 breakpoint is consistent with 
RAG-mediated cleavage at the cryptic heptamer, followed by resection to the right of the 
cleavage site as depicted in Fig. 4F.   It is possible that RAG cleaved downstream of the GTG of 
the heptamer, there was some nucleotide loss, and then joining of this segment to an available 
DNA end in Ch15.  Minimal (1 bp) microhomology was observed at the translocation junction, 
raising the possibility of repair by microhomology-mediated end joining. 
 
Overall landscape of structural variation 
 To obtain a more comprehensive view of structural variation in the tumors analyzed here 
we employed LUMPY, a tool for the probabilistic discovery of genomic structural variants in 
multiple samples (229).   LUMPY analysis was performed on sequences obtained from 21 RAG-
2T490A/+ Trp53-/- or RAG-2T490A/T490ATrp53-/- tumors, 1 RAG-2fl/+Trp53-/- , and 1 RAG-2+/+Trp53-/- , 
tumors. Of the sequences from RAG-2T490A/+ Trp53-/- or RAG-2T490A/T490ATrp53-/- tumors, 15 were 
obtained with the TRAD probe set and 6 with the IGH/TRB probeset (Fig 5A). Sequences from 
the RAG-2fl/+Trp53-/-  and RAG-2+/+Trp53-/-  tumors were obtained the TRAD probeset.  
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Duplications, inversions, deletions, and interchromosomal rearrangements were scored.  An 
overall average of 54 structural rearrangements were detected per tumor sample.  The majority of 
structural rearrangements detected by LUMPY, 481 of 575, or 84 percent, were 
interchromosomal rearrangements, consistent with translocation being the dominant form of 
structural variation within these tumors. Other than the presence of B lineage tumors arising 
solely in the RAG-2T490A Trp53-/- tumors, striking differences were not observed between RAG-




V(D)J recombination is a major source of oncogenic genomic variation in lymphoid cells.  
Indeed, aberrant V(D)J recombination has been estimated to underlie translocations in 40 - 70% 
of human pro- and pre-B cell malignancies (192,230). Such translocations may involve either (1) 
legitimate RAG cleavage at an Ig/TCR gene segment and illegitimate RAG cleavage at a proto-
oncogene, or (2) legitimate RAG cleavage at a pair of Ig/TCR gene segments and cleavage at a 
proto-oncogene by a RAG-independent mechanism (192). We have employed an in vivo model 
of mistimed V(D)J recombination in the mouse as a source of RAG-associated translocations. 
The coupling of V(D)J recombination to the cell cycle is dependent on phosphorylation of RAG-
2 at T490 and its subsequent ubiquitylation and degradation (59-62). This coupling directs RAG-
generated DNA DSBs toward repair by NHEJ. Previous work from this laboratory has 
demonstrated that mice containing the RAG-2 T490A mutation on a p53-null background 
develop lymphoid malignancies characterized by complex, clonal chromosomal translocations, 
often involving antigen receptor loci(62).  
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In this chapter, we characterized genomic rearrangements obtained from lymphoid tumors 
arising in this mouse model.  Our approach for interrogating V(D)J rearrangements and RAG-
mediated structural variation involved targeted, antigen receptor gene-specific hybrid capture 
combined with Illumina sequencing(221). We confirm previous findings of this laboratory by 
showing that in T lineage and B lineage lymphomas from RAG-2(T490A), p53-null mice 
chromosomal translocations are the predominant form of genomic variation.  We extend these 
findings by identifying these rearrangements at genome-wide scale and defining them at the 
nucleotide level(62). 
 
The novelty of our approach lies in its ability to detect endogenously arising translocations in a 
mouse model of mistimed V(D)J recombination.  High-throughput, genome wide translocation 
sequencing (HTGTS) has been used characterize translocations arising after introduction of non-
physiologic DNA DSBs as bait (185,216). Another approach has used hairpin adapters to 
identify DNA double stranded breaks, regardless of the source of breakage, within the genome 
both in cell culture and in vivo (219,220).  This methodology has the advantage of being able to 
detect DNA double stranded breaks in vivo. Our in vivo model and sequencing methodology are 
able to capture and enrich for endogenous, RAG-mediated structural variants. A similar panel 
called myTYPE has been applied clinically to analyze samples from patients with multiple 
myeloma; myTYPE can identify translocations involving the IgH locus(231).  Our general 
approach may therefore have utility in the clinic. 
 
Results presented above suggest that chromosomal translocation is the predominant type of 
structural variation in tumors from RAG-2(T490A), p53-null mice. This is in contrast to an 
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analysis of core RAG-2, p53-null mice in which most reported structural variants were deletions 
(199,200). We posit that this difference can be attributed to the sensitivity of our system in 
comparison to whole genome sequencing studies, the restriction of our analysis to 
rearrangements involving the capture regions, functional differences between the distinct RAG-2 
mutants employed, or some combination of the above. With regard to the first possibility, our 
capture method may enrich for interchromosomal rearrangements whereas these potentially 
infrequent rearrangements are missed within a whole genome sequencing dataset because of the 
rarity of the event or the heterogeneity of the tumor sample. If this possibility is true, it is 
possible that intrachromosomal rearrangements are not the predominant form of structural 
variation in these tumors, but just the predominant source identified within the limitations of our 
methodology. In addition, the filtering method that we used, with which we excluded properly 
paired reads, may have eliminated many small deletions that could have been scored as proper 
pairs.  
 
It remains possible that the differences between our model and the core RAG-2 model with 
respect to structural variation reflect differences between the RAG-2 phenotypes. Core RAG-2 
lacks regulatory the inhibitory domain, the PHD, the degradation domain and the nuclear 
localization region (7,8,17,59-62,199,200).  The PHD mediates allosteric activation of RAG by 
H3K4me3 (17,20,117). Disruption of the inhibitory domain renders RAG activity independent of 
H3K4me3 binding(54). By eliminating these domains localization or activity of RAG could be 
misregulated. It is therefore difficult to know whether the structural rearrangements observed 
result from alternative DNA double strand break repair machinery or from another misregulated 
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RAG activity. Our model allows us to examine the effects of RAG induced double stranded 
breaks outside of G1 and to assess these effects on genomic integrity.  
 
We did not observe many recurrent genomic rearrangements between tumor samples. This was 
in contrast to core RAG-2, Trp53-/- mice which exhibited recurrent deletions in Notcht1, Pten, 
Ikzf1, Jak1, Phlda1, Trat1, and Agpat9 genes (199).  This difference may result from 
undercounting of deletions by our method or by differences in regulation of the RAG-2 variants 
used.  Previous work from this laboratory employed spectral karyotyping and fluorescence in situ 
hybridization to identify translocations TRAD in T lineage tumors from RAG-2(T490A), p53-
null mice(62). The capture sequence method described here also identified a translocation 
involving TRAD.  Analysis of the translocation junction at the nucleotide level implicates DNA 
cleavage by RAG at TRAJ49 within the Jα cluster and a RAG-independent cleavage event 
within the Robo2 locus.  Moreover, the apparent resection of the TRAJ49 signal end is 
characteristic of aberrant signal joints in mice expressing RAG-2(T490A) (62). Our results are 
consistent those of Halper-Stromberg and colleagues, who, employing a similar capture-based 
approach, failed to observe recurrent translocations in cancer cell lines or human primary 
lymphoid tumor samples (221). 
 
As stated above, the ch14:16 translocation between TRA and Robo2 that we identified in T 
lineage thymic tumor is likely a type 2 event.  Although a minimal CAC motif is present about 
20 nt from the breakpoint, extensive end resection in the incorrect direction would have had to 
occur prior to ligation to form the translocation junction that we observed. We favor the 
interpretation that this rearrangement arose from the joining of a RAG-mediated signal end at 
TRAJ49 to a RAG-independent breakpoint at the Robo2 locus.  In accordance with the ability of 
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RAG-2(T490A) to support accumulation of signal ends outside of G0/G1, a signal end could 
have illegitimately been joined to Robo2 giving rise to the structural variant we observed (62). 
The location of Robo2 in nuclear space has not been examined, so it is not known whether these 
two loci colocalize. 
 
The ch12:15 translocation between IgH and downstream of Myc identified in the B lineage 
thymic tumor 2008 is also likely to have arisen from a type 2 translocation, as there is limited 
evidence for a canonical or cryptic RSS surrounding the ch15 breakpoint suggesting the Ch15 
breakpoint may not have been RAG-mediated. Additionally, the breakpoint within the IgH locus 
falls between the Cδ and Cγ3 constant regions but does not overlap with a known switch region. 
Translocations involving Myc and the IgH locus have been documented in healthy patient 
thymus cells (232,233). Additionally, it has been shown that Myc and IgH occupy the same 
location within the nuclear space (174). 
 
Overall, we present a new method to identify structural variation involving antigen receptor loci. 
We employ this approach to characterize structural variants associated with mistimed RAG 
activity.  In so doing we identify endogenous V(D)J recombination events as well as 
translocations involving antigen receptor loci. This methodology can be applied to a variety of 
tumor samples and the analysis utilizes free bioinformatic tools, making this methodology easily 
adoptable by others. The presence of chromosomal translocations involving TRAD are 
reminiscent of those observed in 20% of human T cell acute lymphoblastic leukemia, suggesting 
that these results may shed light on mechanisms underlying this disorder (192).
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Summary and Future Directions 
 
V(D)J recombination is coupled to the cell cycle through the periodic destruction of RAG-2 by 
phosphorylation at T490 and subsequent degradation via the ubiquitin-proteasome pathway. The 
T490A mutation eliminates this phosphorylation site and allows for constitutive RAG expression 
and RAG-generated DNA double stranded breaks throughout the cell cycle. To assess the 
consequences of this uncoupling, we utilized a mouse model containing the T490A mutation 
crossed into a p53 deficient background. These mice exhibited complex chromosomal 
translocations involving antigen receptor loci. To better define the structural variation and 
genomic instability within this model, we employed a capture sequencing-based methodology 
capable of detecting endogenous V(D)J rearrangements and novel translocations involving 
antigen receptor loci. 
 
Since p53 deficient tumors have been well characterized and demonstrated not to exhibit 
translocations, we only sequenced two control tumors using our capture-sequencing 
methodology. However, since we do not have a large sample size of control tumors, it remains 
difficult to draw clear conclusions regarding mistimed RAG activity and structural variation. To 
expand upon this work, we could sequence additional control tumors to draw clearer conclusions 
regarding which rearrangements are specific to the mistimed V(D)J recombination model. 
Another limitation of this study was the small sample size of tumors analyzed using the 
IGH/TRB probe set. Analyzing more tumors with this probe set would be informative and may 
provide us with additional insight into recurrent translocations and rearrangements.  
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Since spatial proximity of loci may play a role in translocations, it would also be interesting to 
culture the tumor cells and perform Hi-C analyses to see if loci involved in translocations are 
located close to each other in nuclear space. Previous studies have identified colocalization of the 
IgH locus and c-myc.   
 
Since all of our analyses were performed on bulk tumor cells, it is possible that we are missing 
some of the rarer structural variants. Future studies could use FACS to isolate the tumor cells 
from the non-tumor cells, and then perform the capture sequencing methodology. This would 
provide an internal control within an animal and could identify differences in structural variation 
between tumor and non-tumor tissue. Additionally, once technologies advance, single cell 
analyses utilizing this probe set and pipeline would be very interesting to identify potential 
recurrent translocations, but this is currently technically challenging due to the large amount of 
DNA needed to perform the pulldown.  
 
Occasionally the RAG-2(T490A), p53-deficient mice developed non-lymphoid tumors. Our 
analyses focused primarily on lymphoid tumors, but future studies could perform histology on 










Figure 1: RAG-2 (T490A); p53 -/- mice develop T and B lineage lymphoid tumors. A, above 
representative flow cytometry plots of thymic tumors obtained from RAG-2(fl); p53-/- controls or 
RAG-2 (T490A); p53 -/- , genotype and mouse number indicated above, stained for B and T 
lineage markers, B220 and CD3 respectively. Gates set based on unstained and stained WT 
C57BL/6J mouse thymus controls. Below flow cytometry plots stained for T cell markers CD4 
and CD8. Gates set based on same controls as above. B, Types of malignancies generated by 
genotype with sample size indicated above. Sample size is indicated above. Other category 
includes any malignancy other than spleen or thymus, i.e. enlarged liver, other solid tumors, 
etc… C, Lymphoid lineage of thymic and splenic tumors plotted by genotype. Phenotypes were 







Figure 2: Design of custom antigen receptor capture. A, Schematic of the biotinylated RNA 
probe design. Probes were designed to span the J and D segments of IgH locus, the D and J 
segments of the TRA and TRD loci. Above Ideogram of mouse chromosomes 12 and 14, with 
antigen receptor locus location indicated by a vertical line. Middle Annotated Immunogenetics 
Information System (IMGT) antigen receptor genes plotted by genomic location. Below Enlarged 
view to demonstrate 5x tiling of RNA probes, illustrated as blue arrows, across the capture 
region. B, Outline of capture sequencing and analysis pipeline beginning with probe design, 






Figure 3: Antigen receptor capture sequencing is able to efficiently identify canonical V(D)J 
rearrangements. A, Example of a V(D)J rearrangement identified in thymic tumor 2008. Above 
Ideogram of mouse chromosome 12, with IgH locus location indicated by a vertical line. Middle 
IMGT known gene IgH J-1 genomic location is plotted and Below discordant and split reads, 
indicated in purple, are aligned to the mm9 mouse reference genome. A discordant read pair is 
connected by a light grey line. Left highlights IgH J-1 location, and right highlights IgH V3-8 
location. B, PCR verification of thymic tumor 2008 V(D)J rearrangement. Left, schematic of a 
successfully rearranged locus with primers indicated as black arrows. Primer combinations and 
predicted product sizes are illustrated below. Right, agarose gel of PCR products with primer 
pairs indicated above the lanes. C, Schematic of an example split read covering the V(D)J 
junction. Above track, a selection of genomic sequence color coded with blue and green being 
included in the split read sequence, black being the flanking genomic sequence, and orange 
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indicating recombination signal sequence (RSS). Middle tracks, linear schematic of genomic 
unrearranged IgH locus followed underneath by a zoomed in version of the rearranged locus 
identified within the split read, color coded with V3-8 in blue, DSP2.3 in purple, J-1 in green, 
and non-templated nucleotides in red. Below portion of the split read sequence spanning V3-8, 
DSP2.3, and J-1 with same color coding as schematic. Below track, portion of sanger sequencing 






Figure 4: Antigen receptor capture sequencing permits characterization of translocations in 
RAG-2(T490A);p53-/-  thymic tumors involving antigen receptor loci. A, Example of a 
translocation identified in thymic tumor 1931 involving an antigen receptor locus. Above 
Ideogram of mouse chromosome 14 and 16, with genomic locations involved in rearrangement 
indicated by vertical lines. Middle UCSC known gene genomic locations are plotted and Below 
discordant and split reads, indicated in purple, are aligned to the mm9 mouse reference genome. 
Left highlights Ch14 involvement in rearrangement, and right highlights Ch16 involvement in 
rearrangement. B, PCR verification of thymic tumor 1931 translocation. Above, schematic of a 
Ch14:16 translocation with primers indicated as black arrows. Primer combinations and 
predicted product sizes are illustrated below. Below, agarose gel of PCR products with primer 
pairs indicated above the lanes. C, Schematic of an example split read covering the Ch14:16 
translocation. Above track, a selection of genomic sequence color coded with blue and green 
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being included in the split read sequence, black being the flanking genomic sequence, and bold 
underline indicating recombination signal sequence (RSS), and bold indicating potential RSS-
like motifs. Middle tracks, linear schematic of genomic unrearranged Ch14 and 16 loci followed 
underneath by a zoomed in version of the rearrangement identified within the split read, color 
coded with Ch14 in blue and Ch16 in green. Below portion of sanger sequencing read confirming 
Ch14:16 translocation. Ch14 is highlighted in blue. D, Example of a Ch15:12 translocation 
identified in thymic tumor 2008. Above Ideogram of mouse chromosome 15 and 12, with 
genomic locations involved in rearrangement indicated by vertical lines. Middle UCSC known 
gene genomic locations are plotted, and Below discordant read, indicated in purple, are aligned to 
the mm9 mouse reference genome. Left highlights Ch15 involvement in rearrangement, and right 
highlights Ch12 involvement in rearrangement. E, PCR verification of thymic tumor 2008 
Ch15:12 translocation. Above, schematic of a Ch15:12 translocation with primers indicated as 
black arrows. Primer combinations and predicted product sizes are illustrated below. Below, 
agarose gel of PCR products with primer pairs indicated above the lanes. F, Schematic of an 
example split read covering the Ch15:12 translocation. Above track, a selection of genomic 
sequence color coded with blue and green being included in the split read sequence, black being 
the flanking genomic sequence, and underline indicating recombination signal sequence (RSS)-
like sequence and bold indicating potential microhomology. Middle tracks, linear schematic of 
genomic unrearranged Ch15 and 11 loci followed underneath by a zoomed in version of the 
rearrangement identified within the split read, color coded with Ch15 in blue and Ch12 in green. 
Below portion of sanger sequencing read confirming Ch15:12 translocation. Ch15 is highlighted 






Figure 5: LUMPY structural variation analyses reveal interchromosomal rearrangements in 
RAG-2(T490A); p53-/- mouse tumors. A, graph of types of structural rearrangements identified 
by LUMPY analysis. RAG-2 (T490A);p53-/-  tumors are indicated below by tumor number, type 
of tumor T thymic tumor or CN cervical node tumor, and probeset used for capture, either TRAD 




Mouse Tumor # Genotype Tumor location Lineage Probe set utilized
1784 RAG2 T490A/+; p53 -/- Thymus T TRAD
1996 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
2077 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
2079 RAG2 T490A/T490A; p53 -/- Cervical Node T TRAD
2083 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
1974 RAG2 T490A/+; p53 -/- Thymus T TRAD
1734 RAG2 T490A/+; p53 -/- Thymus T IgH/TRB, TRAD
1931 RAG2 T490A/T490A; p53 -/- Thymus T IgH/TRB, TRAD
2008 RAG2 T490A/T490A; p53 -/- Thymus T IgH/TRB, TRAD
2139 RAG2 T490A/T490A; p53 -/- Thymus T IgH/TRB, TRAD
2140 RAG2 T490A/T490A; p53 -/- Cervical Node B IgH/TRB
1781 RAG2 T490A/+; p53 -/- Thymus B IgH/TRB
2264 RAG2 WTfl/+; p53 -/- Thymus T TRAD
2341 RAG2 +/+; p53 -/- Thymus T TRAD
1975 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
2418 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
1969 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
1843 RAG2 T490A/+; p53 -/- Thymus T TRAD
1859 RAG2 T490A/T490A; p53 -/- Thymus T TRAD
1829 RAG2 T490A/+; p53 -/- Thymus T TRAD
  
 





Mouse generation and handling.  
RAG-2(T490A) mice (62) and RAG-2 (WT*) controls containing a floxed neomycin resistance 
marker were crossed onto a p53-/- deficient background (Jackson Laboratories) to generate 
RAG-2(T490A) p53 -/- mice and RAG-2(WT*) p53 -/- mice. Mice were genotyped utilizing 
primers from Zhang 2011. All mice were maintained in a pathogen free environment. Mice were 
monitored daily for signs of distress, and then immediately euthanized, dissected, and tumor 
tissue was isolated. Tumor tissue was frozen in liquid nitrogen for further analysis, cultured in 
RPMI in preparation for metaphase analysis, and immunophenotyped by flow cytometry. Cells 
were stained with APC-CD3, V450-B220, PE-CD4, and FITC-CD8 antibodies (Becton 
Dickinson). All flow cytometry utilized a WT 6-8 week old mouse thymus or spleen for gating 
controls.   
 
SureSelect library design.  
Antigen receptor loci genomic locations in the mouse reference genome mm10 were downloaded 
from the international ImMunoGeneTics (IMGT) database and converted to mm9 using UCSC 
genome browser’s LiftOver tool. We designed two sets of probes, IgH/TRB and TRA/D. For 
each antigen receptor locus, we chose to cover the D and J segments plus a 200 bp target window 
immediately flanking the D and J segments. For the IgH/TRB set, we tiled across IgHD1 through 
IgHJ4 and TRBD1 through TRBV31with 200bp extra on each end (mm9 coordinates: 
chr6:41483000-4158570, chr12:114666978-114720181). We utilized 3278 120-mer baits, with a 
total size of 78.792kbp. For the TRAD probeset we tiled across TRDD1 through TRAC, with 
200bp extra on each end (mm9 coordinates: chr14:54732943-54844073). We utilized 4657 120-
	 94 
mer baits, with a total size of 111.144kbp.  We employed five-fold Agilent SureSelect bait tiling, 
with no masking. These baits were used to pull-down these antigen receptor sequences using 
eArray.  
 
Targeted DNA library preparation and sequencing.  
High quality genomic DNA was obtained from either fresh or frozen tumor tissue according to 
GenElute Mammalian Genomic DNA Miniprep Kit manufacturer instructions (Sigma G1N10). 
The Johns Hopkins Genetic Resources High Throughput Sequencing core facility performed 
library preparation, capture, and sequencing. Each gDNA sample was fragmented to 500bp 
fragments using a Covaris E210 system. Sample DNA was end-repaired using, purified via SPRI 
bead cleanup, dA-tailed, and ligated to index-specific, paired end adapters from Illumina. 
Agilent’s SureSelect Target Enrichment System Kit for Illumina Paired-End Multiplexed 
Sequencing was utilized for library preparation and pull-down. 500ng of library was hybridized 
to the custom biotinylated RNA oligonucleotides. Magnetic bead selection was performed to 
capture the RNA-DNA hybrids and RNA was digested according to Agilent’s protocol. 
Remaining captured DNA capture was PCR-amplified. The multiplexed libraries were then 
sequenced on Illumina HiSeq generating an average of 15-16M 250bp paired-end reads across 
the captured region. 
 
Rearrangement identification.  
We first aligned reads to the capture region using BWA-MEM with standard settings(222). On 
average, about 90% of reads mapped to the capture region. Next, utilizing Samtools we removed 
properly paired reads, defined as containing a proper orientation, standard insert size, and both 
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pairs mapping to the capture region(222,223,234). We took the remaining reads, which averaged 
between 2-2.5M reads, and aligned the reads to mm9. On average 99% of these reads mapped to 
mm9. Once mapped, we extracted split and discordant reads using Samblaster and analyzed 
these reads by visualization in Integrative Genomics Viewer(IGV) and by structural variation 
analyses using LUMPY(224,229).  
 
Validation.  
We designed primers to amplify across rearrangement breakpoints. We considered an event 
validated if we observed the expected DNA fragment within the sample but not in the control 
DNA. Additionally, we sanger sequenced these PCR products to confirm the exact sequence of 
the breakpoint junction. We validated both canonical V(D)J rearrangements and structural 
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AstraZeneca, Graduate Student Intern   January 2020-April 2020 
Cell Culture and Fermentation Sciences Department, Biopharmaceutical Development 
o Initiated investigations into molecular mechanisms underlying promising in-house media 
formulations for CAR-T cell cultures 
o Documented and presented results to team via oral and written communications 
o Transduced, expanded, and phenotyped primary T cells ex vivo for CAR-T development 
Johns Hopkins University School of Medicine, Ph.D. Candidate 2014-2020 
PI: Stephen Desiderio M.D. Ph.D. and Carol Greider Ph.D. 
o Initiated and led a project which determined the epigenetic regulation of V(D)J 
Recombination and its role in lymphomagenesis, which resulted in 2 presentations at major 
conferences 
o Developed and optimized flow cytometry-based assay for quantifying V(D)J recombination 
o Designed and optimized a capture-based NGS approach to identify novel translocations and 
genomic rearrangements in a mouse model of mistimed V(D)J Recombination and performed 
bioinformatic analyses 
o Created knock-out and knock-in cell lines and mouse models utilizing CRISPR/Cas9 
technology 
o Secured a $500 travel grant to attend American Society for Hematology meeting  
College of the Holy Cross, Undergraduate Researcher; Summer Fellow  2012-2014 
PI: Ann Sheehy Ph.D.  
o Investigated the antiviral properties of human APOBEC3G and its role in an HIV-1 infection 
which resulted in three presentations at major conferences, 2 presentations at undergraduate 
research symposia, and an honors thesis 
o Mentored and trained 4 junior scientists in both wet-lab practices and presentations  
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Johns Hopkins University School of Medicine 2014- 2020 
 Ph.D. candidate Biochemistry, Cellular, and Molecular Biology 
 Preparing Future Faculty Teaching Academy Certificate         2016 
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TECHNICAL SKILLS  
Cell culture: CAR-T ex-vivo expansion(G-REX), mammalian cell lines, primary human and 
murine cultures, transfection, viral production and transduction, CRISPR/Cas9 editing 
Molecular biology/biochemistry: Western blotting, Southern blotting, molecular cloning, qPCR, 
mutagenesis, DNA isolation/purification, RNA isolation/purification, mammalian protein 
purification, ELISA, in vitro biochemical assays 
In vivo models: flow cytometry, FACS, CRISPR/Cas9 mouse creation, mouse colony 
maintenance 
 
Bioinformatics: Illumina sequencing, NGS analysis, basic bash scripting, basic R scripting 
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Baltimore Brain Connect, Co-founder and Organizer 2018, 2019 
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Science Outside the Lines, Founding Member and Organizer 2017-2019 
o Initiated and founded a 4th grade afterschool arts integration science program in collaboration 
with Henderson-Hopkins elementary school and Johns Hopkins  
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o Lead over 100 graduate student and post-doctoral volunteers in science outreach and science 
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o Organized and executed monthly science demonstrations at local farmers market as committee 
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Johns Hopkins University, Instructor   Winter 2018, Winter 2019 
o Designed, organized, and taught the course “How Viruses Shape Our World” to 50 
undergraduate students  
o Delivered active-learning styled lectures, facilitated in-class discussions and group work, and 
utilized novel pedagogical technology 
 
Goucher College, Collaborative Teaching Fellow    Spring 2019 
o Developed and presented pre-laboratory lectures, created and graded assessments, and assisted 
instructor and students during the laboratory experiments 
 
Johns Hopkins University School of Medicine  
o Graded and lectured as teaching assistant for graduate Molecular Biology course    2017, 2018 
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MR May, JT Bettridge, SV Desiderio. 2020. H3K4me3 binding and relay of an allosteric signal 
to RAG-1 are separable functions of the RAG-2 PHD finger. J Biol Chemistry. May 2020 
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MR May, SV Desiderio. 2020. An antigen receptor-specific capture sequencing method reveals 
structural variations in a mouse model of mistimed V(D)J Recombination. BMC Genomics In 
Preparation- Anticipated submission Aug 2020 
 
ABSTRACTS AND PRESENTATIONS  
MR May, JT Bettridge, SV Desiderio. 2018. Oral Abstract. An Allosteric Mechanism for 
Epigenetic Activation of the V(D)J Recombinase. American Society for Hematology. San 
Diego CA 
MR May, JT Bettridge, SV Desiderio. 2018. Poster. An Allosteric Mechanism for Epigenetic 
Activation of the V(D)J Recombinase. American Society of Hematology Meeting on 
Lymphoma Biology. Washington D.C. 
NK Hussain, MR May, KJ Monk, S Magsamen, RL Huganir. 2018. Poster. Baltimore Brain 
Connect: A Multi-layered Approach to Increasing Public Engagement with Neuroscience and 
Research. Society for Neuroscience. San Diego CA 
MR May. 2014. Poster. Characterization of the Antiviral Function of APOBEC3G. Annual 
American Association for the Advancement of Science Conference. Chicago, IL.  
MR May. 2014. Oral Abstract and invited panelist.  Characterizing Novel N-terminal Domains 
of APOBEC3G. Conference on Retroviruses and Opportunistic Infections. Boston, MA.  
Sheehy, AM and MR May. 2012. Poster. Characterizing the anti-viral function of APOBEC3G. 
XIX International AIDS conference. Washington D.C. 
 
SELECT AWARDS AND HONORS 
2019  Society for Neuroscience Next Generation Award – national award for 
outstanding contribution to public communication, outreach, and education about 
neuroscience  
2019            Baltimore Science Slam – 1st place in science communication competition  
2018  Johns Hopkins Graduate Student Association Travel Award – granted for 
American Society of Hematology meeting  
2018  Johns Hopkins Career Champion Award – nominated for career and student   
support  
2018            Johns Hopkins School of Medicine Student Group Community Service Award  
2017, 2018   Johns Hopkins Student Group Leader of the year- finalist twice  
2015  National Science Foundation Graduate Research Fellowship Program 
Honorable       Mention – prestigious national research award granted to top PhD 
students  
2011-2014    Charles A. Dana Scholarship – prestigious grant for top performing 
undergraduates in academics and service   
2014  The Rev. John W. Flavin S.J. Award in Biology – Only award given to a 
graduating senior biology major for academic excellence and contributions to the 
biology dept.  
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2012  Theresa A. Churilla Biology Book Award – Only award given to a sophomore 
biology major for academic excellence and contributions to the biology dept. 
 
